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1The constmotioix of a reliable immunoassay method for glucagon has 
formed the basis of this thesis. The major factor in the building of a 
good assay was the recognition of the susceptibility of glucagon to attack 
by proteolytic enzymes, a fact which at first escaped the notice of earlier 
investigators. Trasylol, a proteolytic enzyme inhibitor, has proved to 
be an efficient means to prevent this enzyme degradation. The assay was 
able to detect as little as 20 jx^ g. of glucagon.
The application of the assay to measurement of immunoreactive glucagon 
(IRG-) in tissues and body fluids, revealed that IHG was not only present in 
the pancreas but was also detected in much of the alimentary tract, mainly 
the small and Targe intestines. It was apparent also that circulating 
IRG was derived from both enteric and pancreatic sources. Clearance 
studies of glucagon showed that glucagon disappeared rapidly from the body 
and that the liver was a major site for the degradation of glucagon. No 
difference in the clearances of enteric and pancreatic glucagons was noted. 
However immunological differences appeared to be present between the enteric 
and pancreatic glucagons, enteric glucagon reacting less strongly with 
glucagon antibody than pancreatic glucagon.
Yûien assessing the factors which might affect the release of glucagon, 
consideration had to be given to the factors cited above which would 
complicate the studies. It v/as realised that an assessment of factors 
affecting the release of glucagon from both the pancreas and gut would have 
to be undertaken separately. A direct assessment of factors affecting 
the pancreatic release of glucagon was made possible by the application 
of/
2 .
/of a method for isolating the islets of langerhans of rat pancreas. 
Additional use was made of dogs with venous catheters situated in pan­
creatic and gut veins, so that a separate measurement of IHG changes from 
blood draining the pancreas and gut could be made. Studies of animals 
in whom the pancreas was removed were also made, in order that factors 
affecting gut IRG release could be assessed, in the absence of the pancreas.
It was realised also that studies of peripheral circulating IRG levels 
may fail to record changes in gut and pancreatic IRG secretion as much of 
the IRG would be removed in its passage through the liver. Thus many of 
the measurements of IRG were done in pancreatic, jejunal, colonic or portal 
blood prior to its passage through the liver. Wherever possible experiments 
were duplicated both by "in vitro" pancreatic islet studies, and "in vivo" 
dog or human studies, in order that observations could be confirmed by 
different approaches®
Because of certain already established pharmacological actions of 
glucagon on carbohydrate metabolism, the effect of changing glucose 
concentrations on glucagon release was first of all studied. IRG secretion 
from the pancreas was found to increase during acute hypoglycaemia whereas 
no effect was noted on gut IRG secretion. Hyperglycaemia in contrast 
inhibited IRG secretion from the pancreas but once again had no effect on 
gut IRG secretion. Oral glucose did, however, stimulate gut IRG release 
but did not influence pancreatic IRG release.
A study of the effect of the enteric hormones on IRG release was made, 
because of previous reports of the effect of these hormones on insulin 
release. Pancreozymin was found to exert a potent effect on both IRG and 
insulin release from the pancreas, although they had no effect on IRG 
release/
/release from the gut. Secretin and gastrin did not however possess 
any IRG releasing properties from either gut or pancreas*
It was considered probable that glucagon might be an important hormone 
in the control of the metabolic changes during starvation particularly 
through its pha,rmacological actions on gluconeogenesis and lipolysis.
However contrary to this hypothesis, circulating levels of IRG were found 
to fall during starvation in human subjects. That this fall might be 
due to diminished pancreatic IRG secretion was suggested by the finding 
that the release of IRG from pancreatic islets of starved rats was also 
reduced.
Amongst the other factors tested on glucagon release, results were 
obtained to suggest that some of the pituitary-adrenal hormones may influence 
IRG release from the pancreas. In particular adrenocorticotrophic hormone 
probably increases IRG release.
Studies were also made of the inter-relationship of glucagon and 
insulin secretion. Glucagon stimulated insulin release both "in vivo" 
and "in vitro". However simultaneous measurements of glucagon and insulin 
release from pancreatic islets seldom produced a direct correlation in the 
amounts of each hormone released as one might expect if endogenous glucagon 
were stimulating insulin release.
Clinical studies were performed on a family suffering from multiple 
endocrine adenomatosis. Immunoassays revealed that all islet cell pan­
creatic hormones « insulin, gastrin, and glucagon - were involved by the 
process. It was considered that excess glucagon secretion might have 
contributed/
4®
/contributed to glucose intolerance and also hypercalcaemia.
It is concluded that pancreatic glucagon* s physiological role may be 
in the prevention of hypoglycaemia which occurs during short periods of 
fasting. It may act via pancreozymin to prevent reactive hypoglycaemia 
after a meal, especially one which contains a large amount of protein. 
Glucagon's effect on insulin secretion may only operate at near fasting 
or low blood sugar concentrations. It is considered too that glucagon 
is probably a hormone which is of more importance during acute metabolic 
events rather than chronic. This is suggested by the lack of influence 
of chronic starvation on glucagon secretion.
No conclusions could be drawn as to the physiological role of 
enteric glucagon. Enteric glucagon did not respond to the same stimuli 
as pancreatic glucagon. The rise of enteric glucagon seen after oral 
glucose may suggest that its role lies in the stimulation of insulin 
secretion.
The clinical studies in the thesis suggest that abnormalities of 
glucagon secretion may be sought in subjects shovang any of the following 
features:- glucose intolerance, hypercalcaemia, and reactive hypoglycaemia.
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PREFACE
The work on which this thesis is based was carried out from 
September I966 to February 19^8 during the tenure of a research 
fellowship in the Division of Endocrinology and Metabolism, the 
Department of Medicine, University of Washington, Seattle, 
Washington, U.S.A., under Professor Robert H. Williams. Because 
of my previous work on the radio-immunoassay of insulin in 
Dr. A. H. Imrie’s unit of the Royal Infirmary, Glasgow, during 
1963 - 1966, I found the study of glucagon by a radio-immunoassay 
technique a natural extension of my previous interests.
Some of the de,ta contained in this thesis has already been 
published.
"Rise in Serum Immunoreactive Glucagon after Intrajejunal 
Glucose in Pancreatectomised Dogs". Proc. Soc. Exp. Biol, and 
Med., 126 s 813 (l96?) (with J.E.Vance, T.Aoki and H.H.V/illiams).
"A Double Antibody Immunoassay for Glucagon". Diabetes,
11 S 179 (1968) (with W.R.Hazzard, P.M.Crockford, J.E.Vanoe,
R. Chen and R.H.Williams).
"Effect of Glucose Concentration on Insulin and Glucagon 
Release from Isolated Islets of Langerhans of the Rat". Diabetes, 
17 : 187 (1968) (with J.E.Vance, D.R.Challoner and R.H.Williams).
"The Physiologic Role of Glucagon". Proceedings of a 
Symposium on Radio-isotopes in Medicine, Oakridge, Tennessee (1968) 
(with J.E.Vanoe and R.H.Williams).
"Glucagon"/
/"Gluoagon Clearance by the Isolated Perfused Rat Liver".
Proc. Soc. Exp. Biol, and Med., June (1968) (with S®S.Solomon, 
J.E.Vanoe, H.P.Porter and R.H.Williams).
The following papers have been accepted for publication and 
are "in press".
"Effect of Pancreozymin on Insulin and Glucagon Levels in 
Blood and Bile". Amer. J. Physiol, (with J.E.Vanoe, A. Morgan 
and R.H.Williams).
"Effect of Starvation and Refeeding on Serum Immunoreactive 
Glucagon and Insulin Levels". J. Lab. & Clin. Med* (with J.E. 
Vance and RaH.Williams).
"Effect of Starvation on Insulin and Glucagon Release from 
Isolated Islets of Langerhans of the Rat". Metabolism, (with 
J.E.Vanoe and R.H.Williams).
I have been primarily responsible for the v/ork which is in 
this thesis. However most work in medical research to-day is 
the result of enlightened collaboration. Especially would I 
like to record thanks to Dr. James E. Vance who was my colleague 
in many of the projects recorded in this thesis. I am most 
grateful for the opportunity I had to work in the department of 
Professor Robert H. Williams, a man of brilliant inspiration and 
magnificent enthusiasm. Mrs. Barbara Hickernell and Mrs. Susan 
Page provided technical assistance of the highest class. Doctors 
A. Morgan, T. Aoki and K. Dinstl, from the Department of Surgery, 
University/
6
/University of Washington, made their surgical expertise available 
to me during the many dog experiments which required surgical 
skill. I would like to thank Dr. A. H. Imrie and Professor 
E. M, MoGirr who provided me with the necessary opportunities 
and encouragement which enabled me to pursue my research interests. 
Throughout the thesis I have tried to maice it clear to whom I owe 
gratitude. Finally the thesis would not have been possible if 
it were not for the able assistance of members of ray family 
which resulted in the typing and final preparation of the 
manuscript.
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INTRODUCTION
Although glucagon has been available in relatively pure form
for some years, and its primary structure determined as long ago 
•1
as 1956 , there remains controversy as to the physiological role
of this hormone* Glucagon's pharmacological actions have been
2 3 3  
well studied. Glycogenolysis , gluconeogenesis , insulinogenesis ,
and lipolysis^ have all been defined as actions of the hormone.
However, although these properties are seen under certain
pharmacological and experimental conditions, it is less certain
vfhat role glucagon may have in the intact organism. The lack
of a precise and reproducible assay method for the hormone halted
progress along these lines* When Yalow and Berson in 1959
first described the immunoassay technique for insulin, the way
was clear for the application of the method to other polypeptide
hormones. Unger et al (1961)^  first described an immunoassay
method for glucagon but application of the method to the assay
of the hormone in biological fluids was made difficult by the
instability of glucagon when exposed to proteolytic enzymes, and
by the minute amounts of glucagon present in the circulation
which called for high degrees of sensitivity. Hence progress
has been slow in accumulating data from the immunoassay of
glucagon, and partly due to a lack of appreciation of the
difficulties encountered in the assay much misleading and often
erroneous/
/erroneous information has been obtained.
It is the purpose of this thesis to report the construction 
of a reliable immunoassay for glucagon with a sensitivity beyond 
any yet reported. Utilising this assay studies have been made 
of the role of glucagon in health and disease.
Chapter 1 deals with the original methods used in the thesis. 
The construction of. the immunoassay for glucagon is described 
and discussed in detail. A method for isolating islets of 
Langerhans from rat pancreas is also described and the useful­
ness of this model in the study of glucagon metabolism is stressed.
Chapter 2 is concerned with the measurement of glucagon in 
body fluids and tissues. Factors affecting the clearance and 
degradation of glucagon in the body are studied. The presence 
of glucagon in the gut as well as the pancreas is described.
Chapter 3 is the main body of the thesis. Here, various 
factors affecting the release or secretion of glucagon are 
studied. These factors include glucose concentration, various 
enteric hormones, starvation and some pituitary-adrenal hormones. 
In this chapter too, is described the effect of glucagon in 
stimulating insulin secretion.
In chapter 4 u family is described with multiple endocrine 
adenomatosis, where all the islet cell hormones, insulin, gastrin 
and/
/and glucagon are affected by the process.
In chapter 5 the author attempts to summarise the work in 
the thesis and draw broad conclusions.
1 2
HISTORICAL REVIEVY OF GLUCAGON
13
7
In 1924 Kimball and Murlin noted that when most commercial 
insulin preparations are injected intravenously, the typical 
hypogiycaemic effects were preceded by a short period of 
hyperglycaemia. This fleeting rise in glucose concentration 
was due to the presence of an impurity named "glucagon" or 
"mobiliser of sugar" by Murlin and collaborators^, who first
investigated its properties and attempted its purification in
" 91929* During the same year, Burger and Kramer in Germany
performed studies to show that the transient hyperglycaemia that
followed injection of certain insulin preparations wa,s due to a
glycogenolytic action on the liver.
The findings of these workers were confirmed and extended in
several laboratories, and soon it became apparent that glucagon was
a substance endowed with characteristic physiological and chemical 
10 11properties  ^ . This led finally to the announcement by Staub,
12Sinn and Behrens in 1955 that they had purified and crystallised 
glucagon.
Glucagon has a molecular weight of 3485 and is a straight- 
chain polypeptide containing 29 amino acid residues with histidine 
at the N terminal and threonine at the C terminal (Figure 1).
Site of Origin of Glucagon
7 14 15The hyperglycaemic action of pancreatic extracts  ^ ' ’
immediately calls attention to the pancreas as the site of origin 
of glucagon. The A cells of the pancreatic islets appear to be the 
source/
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/source of glucagon. This has been demonstrated by fluorescent
16
antibody studies . In addition tryptophane has been demonstrated
17histochemically in the A cells of rabbit pancreas , while B cells
give a negative reaction. These findings suggest that this
method demonstrates glucagon within the A cells since it has a
high tryptophane content, whereas this amino acid is absent from
the insulin molecule.
Glucagon has also been detected in the alimentary tract by 
18,19
bioassay methods ' . Since the introduction of the immunoassay
20 21 o
methods this work has been confirmed ' Evidence is beginning
to accumulate that glucagon extracted from the alimentary tract may
20be different from pancreatic glucagon. Unger et al , Samols et
21 22 
al and Schopman et al ~ all suggest an immunological difference,
23
Unger et al ' in a recent study suggested that glucagon from the 
gut had biological differences with pancreatic glucagon in addition 
to immunological ones, and concluded that glucagon from the gut 
should be referred to as "glucagon-like immunoreactivity".
Biological Properties of Glucagon
Studies to discover the biological properties of glucagon have 
been based on the injection of pure preparations of glucagon from 
the pancreas into intact animals or experimental models. This work 
although providing fundamental knowledge about glucagon suffers from 
the fact that often very large and pharmacological amounts of 
glucagon were used to produce effects. Therefore it is not often 
possible/
16
/possible to extrapolate the results to the physiological state.
Injection of glucagon produces hyperglycaemia^. This effect
is probably mediated via glycogenolysis as simultaneous glucose
determinations in the blood of the suprahepatic vein, the portal
vein, and the aorta in the dog have shown that glucagon causes an
24 25increase in net hepatic glucose output  ^ . In liver perfusion
systems glucagon has been shown to have a profound glyoogeno-
2
lytic effect. Indeed, Sokal et al have found the glycogeno­
lytic effect of glucagon to be greater than that of epinephrine, 
and have shown that glucagon even in the very low concentration 
of 0®4 pg.per L of plasma, which may in fact lie in the physio­
logical range, still leads to glycogenolysis. Glucagon possibly
I t
initiates glycogenolysis by stimulating the formation of 3 , 5 >
cyclic adenosine monophosphate, and hence the conversion of
26
inactive phosphorylase B to the active phosphorylase A . While
the effects of glucagon on liver phosphorylase, liver glycogen,
and glucose output have been reasonably well established, its
effect on skeletal muscle have been more difficult to ascertain.
Evidence does appear to indicate, however, that glucagon has no
direct effect on phosphorylase activity, glycogen content, and
glucose metabolism of skeletal muscle, although it has been
reported that glucagon causes a reduction in the glycogen content
27 28
of the perfused rat heart ^
Glucagon/
17
/Glucagon has been shown in the rat isolated liver perfusion
system to promote gluconeogenesis^. This is supported by other
work which shows that glucagon reduces blood amino acid concen-
tration^^*^^'^^, and increases the incorporation of G^^ from
32
labelled glycine into liver glycogen .
Most reports suggest that glucagon may inhibit fat synthesis 
and accelerate fat mobilisation. For example, it has been 
reported that glucagon inhibits the incorporation of acetate,
33glucose, and fructose into fatty acids and cholesterol of liver 
and adipose tissue^^, decreases liver fat, promotes the release
35,36,37
of fatty acids and glycerol from adipose tissue , and
increases the concentration of free fatty acids in plasma^^.
Perhaps the most exciting and even surprising new property
for glucagon has been its ability to stimulate insulin secretion,
independent of any hyperglycaemia produced^^*^^. Pharmacological
doses of glucagon have been used in these experiments, but recently 
41Ketterer et al have shown that physiological amounts of glucagon, 
infused into the portal vein of dogs, will cause an insulin rise. 
Glucagon Excess and Deficiency States
Sometimes the role of a hormone can be deduced from states 
known to be associated with excess or deficiency of the hormone. 
Pure glucagon deficiency has not been documented in man, mainly 
due to an inability to recognise the condition. Pancreatectomy in 
man/
18
/man results not only in diabetes mellitus due to the absence of
the beta cells, but also insulin sensitivity and low insulin
requirements which may be due to glucagon lack^^. Mirsky et al^^
found that pancreatectomy in the fowl produced no appreciable
change in the blood sugar concentration and Mikami and Ono^ '^
removed the alpha, cell containing pancreatic lobes in chickens, and
progressive hypoglycaemia developed after several hours, the birds
dying' in hypogiycaemic convulsions 12 to 36 hours after surgery.
Glucagon excess states can be artificially produced by the
repeated injections of large doses of glucagon and this has been
done in both experimental animals"^^ and man^^« A mild diabetic
state of maturity onset type results. Glucagon excess states have
also been reported in association with some pancreatic tumours*
One patient with a pancreatic tumour has been documented with high
levels of glucagon by immunoassay in her plasma, tumour and 
47métastasés * This patient presented with mild diabetes mellitus. 
The Assay of Glucagon
The above studies, although emphasising the potency of 
glucagon as a hormone, fail to define the physiological role and 
behaviour of the hormone. The construction of a reliable assay 
method is necessary for further understanding. Bioassay methods 
for the hormone are tedious and often imprecise and insensitive. 
Recent methodological advances in the field of immunology^^ have 
made/
/made possible the development of highly specific and sensitive
techniques for identification of various peptide hormones, and
for their measurement in plasma^^^^'^'^^*^^.
Because of the relatively weak antigenicity of glucagon, its
52
rapid degradation in plasma , and the demonstration of immunological
20 21
glucagon-like activity in gastro-intestinal extracts '“ , the
glucagon radioimmunoassay has presented major problems in technique
and interpretation to potential investigators. In addition it is
possible that even a most sensitive radioimmunoassay may be unable
to detect possible physiological changes in glucagon in peripheral
41blood, for Ketterer et al have shown that when glucagon was
injected into the portal veins of dogs in amounts sufficient to
produce biological effects, changes in serum glucagon could not be
detected in the peripheral blood. This reduction in the
peripheral compared to portal blood levels being due mainly to
hepatic degradation of glucagon^^’ and dilutional effects.
Thus, although Unger et al^ described a glucagon radio-
iimnunoassay as long ago as 196I, much of the earlier work utilising
this assay may have given misleading data, because the destructive
effect of serum on glucagon whether labelled or not, was not fully
5 5
appreciated. It was in fact Unger and his colleagues in 196? 
who first called attention to the use of Trasylol (Bayer Ltd) a 
proteolytic enzyme inhibitor, to protect against the degradation 
of/
/of glucagon by serum. Studies utilising the rad i o immuno as say 
of gluoagon a,re few, and because the majority of these assays were 
performed without Trasylol and without the knowledge that there 
were 2 circulating types of immunological glucagon reactivity, 
it is impossible to accept many of these results as showing
56completely reliable data. The work of Samols et al who
reported a rise in peripheral blood glucagon levels in man after
oral glucose is open to the criticisms quoted above. There is
57only a single study by TJnger et al employing the immunoassay
to assess the effect of hypoglyoaemia on glucagon secretion, but
this study which shows a, rise in glucagon levels during hypo-
glycaemia also did not incorporate Trasylol within the assay.
58
A study by Unger et al reporting a rise in glucagon levels
during starvation in man is open to the same criticism. Recent
55work by Unger et al cannot be faulted in these respects, and 
shows that pancreozymin stimulates glucagon release, which opens 
up anexciting relationship between the pancreatic and enteric 
hormones.
MATERIALS AND lÆETHODS
The following methods and materials which were not original
were used throughout the Thesis and will not be referred to again.
The methods and materials which were peculiar to each particular
chapter will be described in these chapters.
Insulin in plasma or in incubation media was assayed by a 
59modification of the double antibody radioimmunoassay technique
of Morgan and Lazarow^^ using a human insulin standard (Novo
Terapeutisk Laboratory) for assay of samples containing human or
rat insulin, and canine insulin standard for assay of samples
containing canine insulin.
Plasma glucose was measured by the ferrioyanide method in
a Technicon Autoanalyser, Plasma free fatty acids were assayed
61
by a microcolorometrie method , Serum acetoacetate was 
measured by the method of Rosenthal^^ as modified by Walker^^,
C H A P T E R  1
DESCRIPTION OP ORIGINAL METHODS USED IK THESIS
C H A P T E R  1
SECTION 1
A DOUBLE ANTIBODY RADIOIMMUNOASSAY
FOR GLUCAGON
25
smmjR-Y
A brief intioduction to radio inmiuno as says in general is
given. This is followed by a detailed description of a double
antibody glucagon radioimmunoassay. Guinea pig antiserum
allowing the assay of 2500 unknovms per ml. of undiluted serum
was induced by biweekly immunisation. Glucagon was iodinated 
125with I and purified by elution from a cellulose column,
maximal immunoprecipitability approximating to 80^. Standard 
curves in buffer were sensitive to purified glucagon in amounts 
of less than lOOppg.
Rapid degradation of labelled glucagon added to human 
blood was demonstrated. Trasylol was confirmed as an effective 
inhibitor of this degradation. Endogenous plasma immunoreactive 
glucagon (IRG) appears less labile and may have interfered with 
the quantitative detection of unlabelled exogenous beef»pork 
glucagon in plasma recovery studies.
In order to study the behaviour of gluoagon, it was 
considered essential to construct a reliable assay method for 
the hormone. The introduction of a radioimmunoassay method 
for insulin by Yalow and Berson in 196O opened the way for 
adaptation of the method to the assay of other polypeptide 
hormones.
Radioimmunoassays have as their basis free competition 
between isotopically labelled and unlabelled hormone for binding 
sites to an antibody produced against the hormone. The anti­
body titre remains constant and is chosen so as to only bind 
part of the labelled and unlabelled hormone. The concentra­
tion of labelled hormone also remains constant, so that the 
only variable is the concentration of unlabelled hormone. As 
the concentration of unlabelled hormone rises so will this dis­
place labelled hormone from the binding sites, resulting in loss 
of radioactivity by the antigen-antibody complex. With this 
knowledge a standard curve can then be constructed.
The construction of a radioimmunoassay therefore requires:»
(1) a pure supply of standard hormone,
(2) a hormone labelled with a suitable radioactive isotope in 
such a way that the hormone remains stable, relatively 
undamaged and retains immunological reactivity, and
(3) the production of an antibody against the hormone.
In/
/in addition the conditions of the assay have to be such as
to permit the antigen-antibody reaction to proceed in an optimal
way, and precautions must be taken to prevent damage to the
hormone during the procedure.
During the assay the "free" hormone and the hormone bound
to antibody (the "bound" hormone) must be separated. The
original method which accomplished this was the ohromato-
5electrophoresis technique of Yalow and Berson . This method, 
although an excellent one, is rather tedious and requires 
elaborate apparatus. A method which enjoys greater simplicity 
and speed is the "double antibody" technique introduced by 
Morgan and Lazarow^^ and Hales and Handle^^' in 1963» This 
method employs a second antibody raised against the gamma 
globulin of the animal in v/hich the hormone antibody was pro­
duced, Vdien this anti-gamma globulin or second antibody is 
added to the hormone - antibody complex, a precipitate results 
which can be separated by centrifuga/bion as in the Morgan and 
Lazarow technique or by filtration as in the Hales and Randle 
method. The double antibody technique of Morgan and Lazarow 
for insulin was adapted here for the gluoagon assay.
Methods and Materials
(A) Glucagon The glucagon used for immunisation of guinea pigs 
preparation of standards, iodination, and addition to blood 
or serum was of beef-pork origin and was kindly supplied by 
Dr. Walter Shaw/
Dr. Walter Shaw, Eli Lilly and Company (Lot 258-234B”
167- 1).
(s) Immunisation Glucagon antibodies were produced in 500-800 gm, 
guinea pigs by bi-weekly axillary and inguinal subcutaneous 
injection of 1 mg. of crystalline glucagon dissolved in 
borate buffer, pH 9*2 and emulsified in 1 ml. of Freund's 
complete adjuvant. Antiserum (anti-guinea pig serum in 
rabbits - AGPS-R) was prepared in adult v/hite rabbits by 
monthly injection of partially purified guinea pig 
globulin.
(G) Iodination and purification of gluoaf3:on Grystalline
glucagon,. 10 jig. dissolved in 0.1 H Ha OH and diluted in
1 25veronal buffer was iodinated with 2 mC.I by the method
65
of Hunter and Greenwood .
Of the several methods of purification tried, the cellu­
lose column method proved the simplest, quickest and best* 
Dialysis for 2 hours in 18 X 32 Visking casing, boiled and 
acetylated, resulted in significant loss through the casing. 
Sephadex G - 10 and G - 25 yielded 2 and 3 pealcs of radio­
activity respectively5 however the immunoprecipitability 
and yield was inferior to the simpler cellulose column 
technique.
125The glucagon - I was purified by elution from a 3-5 cm. 
cellulose column^^ with serial veronal and 5^  bovine serum 
albumin/
/albumin washes of 1 ml. each. The subsequent 4 aliquots 
were pooled, diluted I14C with veronal buffer, and frozen until
125use, 50 pl* of the diluted glucagon - I containing approxi­
mately 625 pipg, with an estimated specific activity of 
68 mO/mg. The purified glucagon - was 70 - O^fo
immunoreactive with guinea pig antiserum (GPAS).j the
use of more concentrated antiserum did not appreciably 
increase immunoprecipitability above this level, the remain­
ing radioactivity not precipitated by antibody presumably 
representing glucagon altered during iodination to a degree
preventing immunoprécipitation with GPAS-AGPS-R. Each
125iodination provided sufficient glucagon - I for more
than 50 100 - tube assays. Immunoprecipitability of the 
125
glucagon - I declined by approximately 10^ o over a six 
week period.
(d) The immunoassay An adaptation of the double antibody 
technique of Morgan and Lazarow^^ was employed. The 
buffer utilised was 0.05 M veronal, pH8.6, with merthiolate 
1:10,000, to which bovine serum albumin was added to a 
concentration of O^ Zjfo to prevent glassware absorption of 
glucagon. Sodium versenate, 0.01 M was added to the 
medium to inhibit an inactivator of the second antibody 
system^^. All reagents, unlcnowns, and glucagon standards 
in/
/in buffer were stored at - 20°C end thawed immediately 
prior to use.
During preparation of the assay all reagents and reaction 
tubes were maintained in ice baths.
To the tubes were added sequentially:
(1) Buffer with EDTA, 350 pi;
(2) Glucagon-I*^^^, 50 pi;
(3) Trasylol, 1000 KIU in 50 pi; (vide infra);
(4) Standard or unlcno^ vn, 250 pi;
(5) OP AS 50 jul. in suitable concentration which usually was 
such as to be able to precipitate approximately
30/ of the labelled glucagon in the absence of 
competing unlabelled glucagon. The titre varied 
from 1:100 with some antibodies to 1:500 with other 
antibodies. The final dilution of the OPAS in the 
assay therefore varies from 1:1500 to 1:7500.
After incubation at 4^0 for 24 to 36 hours, second antibody was 
added and a further 6 hour period of incubation at 4^0 was 
allowed prior to cold centrifugation and removal of the supernatant. 
Precipitates were then washed with buffer and their radioactivity 
counted in a well-type auto™ga,mma spectrometer.
Results
(a ) Immunisation Guinea pigs proved reliable producers of 
glucagon antibodies, the titres achieved within 2 to 3 
months/
/months in 3 out of 4 of the animals allowing the assay of
between 2000 and 8000 unknowns per ml. of undiluted. OP AS. 
Monthly booster injections a week prior to bleeding maintained 
adequate titres for over 6 months. Although with 
protracted immunisation several animals developed insulin 
antibodies due to the minute quantities of insulin 
contaminating the glucagon, a total lack of insulin cross- 
reactivity in the glucagon assayed allowed the continued 
use of such antisera.
(B) The assay in buffer for the construction of a standard curve.
( 1 ) Tiie role of Trasylol in the standard curve system
Trasylol (P.B.A. Pharmaceuticals) is a basic polypeptide
which has been shown to inhibit plasminogen and plasmin,
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principal degraders of glucagon in plasma . Loss of 
immunoreactive glucagon (IRG) is demonstrated in figure 1 
on incubation with plasmin, but the destruction is inhibited 
by Trasylol.
In the chromato-electrophoretic immunoassay system,
6sEisentrant, Whissen and Unger , have demonstrated the 
inhibition by Trasylol of glucagon degradation during 
incubation. The effect of Trasylol in preserving
125glucagon-I immunoprecipitability in the double antibody 
standard curve system (containing no serum or pla.sma unlmown) 
is/
FIGURE 1
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INHIB ITION BY TRASYLOL OF 
PANCREATIC GLUCAGON DEGRADATION BY PLASMIN
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Incubation of glucagon with plasmin (2.5 pg./ml.) results 
in loss of glucagon, whereas Trasylol (1000 KIU) prevents this 
loss. Insulin is not affected by plasmin. Incubations were 
conducted in veronal buffer pH 8.6 at 37^0, in a shaking water 
bath.
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/is illustrated in Figure 2a, which depicts curves prepared 
with and without added Trasylol, a small hut consistent loss 
of precipitable radioactivity being recorded at all levels 
of ahded unlabelled glucag’on in the absence of Trasylol.
(2) Duration of the Incubation The initial reaction reached 
a plateau of maximal immunoreactivity at 24 hours of incu­
bation at 4^1", no significant change being detected over 
the ensuing 72 hours (Figure 3)» This plateau reflected 
the stability of the glucagon-antibody complex (in the 
presence of Trasylol) over prolonged periods of incubation. 
The presence of unknown serum in the medium did not affect 
the time at which the plateau was reached. Consequently 
at least 24 hours were routinely allowed for the first 
antibody reaction*
The second antibody reaction reached a plateau of 
maximum immunoprecipitability by 2 hours of incubation at 
4°C. A minimum of 6 hours for the second antibody reaction 
was allowed for the present studies in order to maximise 
agglomeration of the precipitate for optimal separation by 
centrifugation and décantation.
Both first and second antibodies may proceed simul­
taneously in the presence of the required reactants^^. 
Therefore, certain studies were conducted in which both 
GPAS/
I
§
I
I
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FIGURES 2a and 2b
Buffer + Trasylol (2000 KIU) 
Buffer alone
30-%
20 -
10
 ^ o - -o Serum ( 300 X ) + Trasylol ( 2000 KIU )
% Serum alone
\o 
\
\
v>X ( b )
*
500 1500 2500
Glucagon ( f^ fiq added )
Figure 2a The effect of Trasylol upon the standard curve.
125The loss of precipitable glucagon-I in the absence of Trasylol 
maybe attributed to the degrading factors in the GPAS and AGPS-R.
Figure 2b Parallel studies in the presence of added human serum.
The marked additional glucagon degradation introduced by serum is 
completely prevented by the presence of Trasylol in adequate amounts.
FIGURE 3
I
I Buffer plus Trasylol, 2 000  KIU 
o— o Serum plus Trosylol, 2 0 0 0  KIU
2"^ antibody reaction 6 hours
—I— I— I—
30 42
Hours
54 66
—I
78
A study of the duration of the first antibody reaction.
The distance between the origin and the initial values of the 
curve represents the time allowed for the second antibody reaction, 
(the first antibody reaction proceeding concomitantly during this 
interval).
/gPAS and AGPS-R were added on the first day of incubation. 
This modification did not affect precision or the nearly 
quantitive glucagon recovery from plasma (vide infra).
(3) The standard curve Glucagon standards containing from
1250 to 1500 yipg. inhibited the immuno reactivity of glucagon-I 
in a manner so as to allow the construction of a smooth 
standard curve, as depicted in Figure 4- The curve 
illustrated was drawn through points of mean per cent
125
glucagon-I precipitated in 6 consecutive assays performed 
in triplicate.
The standard curve assays were analysed as to the error 
of replicate determinations within a single assay (precision) 
and that introduced by day to day variability, as represented 
by the standard deviation of the mean slopes between points 
on each curve and of the mean percentage of labelled glucagon 
bound at each level of added unlabelled hormone (Table 1).
The precision was calculated among triplicates according to
69
the method of Youden . The sensitivity of the system to
purified glucagon was then determined as that amount 
significantly different (p = .05) from zero (or lower
standard at other points of the curve) as given by
2 2 ^
t(S^  + 8g ) where t is I.96 and and are the 
expression of precision (standard deviation) for the points 
bounding/
40-1
3 5 -
0100 200 500 800 1000 1500 2000
Added Uniabçlled Glucagon {
The gluoagon immunoassay curve• The curve depicted was
drawn through points representing the mean percentages of 
125
glucagon-I bound in 6 consecutive assays#
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/bounding the range of added glucagon in question# The 
value of this expression was then referred to the mean
65
curve to allow translation into }yg# of added gluoagon « 
The resulting calculated sensitivity for triplicate 
analysis varied from a low of 20 ppg* for 0 /A^ g* added 
glucagon to 110 ppg. for I5OO ppg added glucagon#
A flow diagram for the glucagon radioimmunoassay is 
depicted in Figure 
(0) Application of the assays The measurement of IRG in blood,
(a) The requirement of Trasylol. The addition of serum or
125plasma to incubates containing glucagon-I greatly 
enhances the glucagon-degrading capacity of the system, 
thereby increasing the requirement for Trasylol to a level
which will provide maximal inhibition enzymes» In the
absence of an adequate Trasylol concentration, much of the 
labelled glucagon becomes non-immunoreactive. Figures 2b 
and 6 show the effect of Trasylol in preventing loss of 
immunoprecipitability when exposed to human sera» Figures
7 and 8 show the effect of Trasylol on increasing the
125 125'
recovery of insulin-I and glucagon-I respectively
when exposed to serum and pancreatic juice respectively.
125Serum has little effect on insulin-I but has a marked
1 25destructive effect on glucagon-I »
125As a result of damage to glucagon-I immunoreact­
ivity by serum, the apparent immunoreactive glucagon (IKG-) 
coneentration/
Figure 5
Flow D iagrom  For The Double A ntibody Glucagon Im m uno assay.
( I )  2 0 0  / i l  bu ffer ( veronol 0 5  M , pH 8 . 6 )  with ED TA  ( . 0 3  M )
(2 )  5 0  fi\ Trasylol ( 1000  K .l.U . )
+
( 3 )  5 0  /i l Glucagon -
+
( 4 )  2 5 0  /il standard (in  buffer without E D T A ) or unknown E*>X;':v
Glucogon -
(5 )  5 0  / i l  GPAS | : I2 5
4 °  3 6  hours
Glucagon
Guinea pig 
a n ti -  beef “ pork 
glucagon an tib ody
6  hours
Discord supernotant
( I )  5 0 /i l  normal GPS 1 : 2 5  
+  (2 )  5 0  / i l  bu ffer with E D TA  
( 3 )  5 0 /i l  A G P S -R
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R abbit
a n ti-g u in e a  pig 
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Count p rec ip ita te
A flow diagram for the double antibody gluoagon radioimmunoassay,
3 6 0 i
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FIGURE 6
EFFECT OF TRASYLOL ON THE DEGRADATION OF 
1125 GLUCAGON IN 2 HUMAN SERA
340-
200 400  600 800 1000 1500 2000 4 0 0 0
Trasylol (units)
1 25
The amount of glucagon-I precipitated in the presence and 
absence of Trasylol. Maximum immunoprecipitability was 
achieved in these two human sera by as little as 100 KIU 
Trasylol.
FIGUES 7
I
î§
PERCENT in s u l in  BOUND BY ANTIBODY IN 
PANCREATIC JUICE AND SERUM AS COMPARED 
WITH BUFFER
Buffer Serum Pancreatic juice
/ " ■ V t—  -------------------------
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80-j
60"
40i
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H- 4- H-
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125Insulin antibody binds almost all of insulin-I in the presence
of serum and pancreatic juice stored frozen (inactivated).
Wcien pancreatic juice is activated by allowing to stand at room
125temperature much of the insulin-I is degraded.
FIGÏÏRE 8
PERCENT l'25 GLUCAGON BOUND BY ANTIBODY IN 
PANCREATIC JUICE AND SERUM AS COMPARED 
WITH BUFFER
glOOn
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m 125There is much loss of glucagon-I when exposed to serum
hut this is almost completely overcome by the presence of
Trasylol. Trasylol also helps to overcome the degrading
125effect of pancreatic juice on glucagon-I
/concentration becomes falsely elevated when the precipitable
radioactivity in a serum or plasma unknown is compared to the
125much greater level counted in the standards whose gluoagon-I 
has been left virtually intact. This effect is prevented by 
the presence of Trasylol in adequate concentration. This role 
of Trasylol in the measurement of serum IRG was demonstrated in a 
study of 19 fasting human sera assayed in the absence as well as 
in the presence of Trasylol. In those sera an apparent glucagon 
concentration of 3^90 + 250 ppg. (S.E«M* ) per ml. measured without 
Trasylol was reduced to 256 f 117 ppg. per ml. by its presence.
Plasma glucagon-degrading activity was variable; con­
sequently the use of less than optimal amounts of Trasylol affected 
relative as well as absolute levels of IRG measured in plasma of 
different individuals (Figure 9)* However, in studies utilising 
up to 4000 KIU Trasylol, no additional effect beyond that achieved 
with 1000 KIU per 250 pi. plasma was detected. Therefore a level 
of 1000 KIU per 250 pi. plasma or serum was adopted as a minimum 
for the routine assay procedures.
Fpsilon-amino-caproio acid was found to be ineffective in
125preventing glucagon-I degradation by serum. Lima bean trypsin 
inhibitor was on occasion as effective as Trasylol but its effect 
was/
Plasma Glucagon- Effect of Trasylol Concentration
\
I1600-11400
% 1200 
1000
P
800
I
&  6 00 -
^  400
I 200
I
500 1000
Trasylol concentration (K.I.U. )
The effect of Trasylol upon measured plasma glucagon in 6 
individuals* The relative IRG concentrations among the 
individuals varied as the Trasylol concentration was increased, 
reflecting inequality in their levels of plasma glucagon-degrading 
factors*
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/was never as consistent*
(b) The degradation of glucagon during the collection and 
processing of blood specimens ____ _____
125The degradation of gluoagon-I during the collection 
and processing of blood specimens was assessed in 6 indi­
viduals utilising labelled glucagon present in the syringe 
before venepuncture. The contents of the syringe were 
processed in 6 different ways to determine the effect of 
time, temperature and Trasylol upon glucagon degradation, 
the per cent recovery being calculated by comparison with 
that from a syringe filled with buffer rather than blood.
Twice the usual concentrations of both first and second 
antibodies were used in order to assure maximal immuno­
précipitation despite the competition exerted by endogenous 
glucagon.
As recorded in Table 2 (column 1), the time at which 
Trasylol was added, as well as the method by which the blood 
specimens were processed, significantly affected the recovery 
of labelled glucagon. Expeditious collection and immediate 
exposure to Trasylol preserved 90^ of the immunoprecipitability 
of labelled glucagon, even if as long as 60 minutes elapsed at 
ice bath temperatures between collection of the blood and 
separation of the plasma. In the absence of Trasylol, the 
short/
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/short period required for centrifugation and separation 
(less than 30 minutes) resulted in significant (p Z^.001) 
though minor (9^ ) degradation with progressive deterior­
ation in immunoprecipitahility occurring even at ice hath 
temperature as the time between collection and exposure to
Trasylol increased. Degradation of approximately one third
125of the gluoagon-I was incurred by allowing the blood to 
clot at room temperature and separating the serum before 
its exposure to Trasylol.
However, parallel studies of the native IRG concen­
tration in blood specimens treated indentically to those 
to which labelled glucagon was added failed to show similar 
degradation of endogenous IRG despite the absence of 
Trasylol (Table 2, column 2).
(c) Storagre of Specimens A better recovery of plasma glucagon 
resulted if measured plasma or serum samples were separated 
into Trasylol (250 pi. plasma per 1000 KID Trasylol) and 
stored in the deep freeze until assay, than if the samples 
were stored without Trasylol (Figure 10).
(d) Plasma recovery studies Recovery of the unlabelled beef- 
pork glucagon standard, added to human plasma containing 
Trasylol (1000 KIU per 250 pl.), was measured using a 
standard curve with a range of 100 to 1500 ppg. In the 
calculation/
ac
FIGURE 10
EFFECT OF STORAGE WITH AND
WITHOUT TRASYLOL ON IMMUNO- 
REACTIVE GLUCAGON LEVELS IN 
SERUM
With
trasylol
if 1 “
Without
trasylol
The estimates of IRG in serum stored with Trasylol (250 pi. 
per 1000 KIU Trasylol) were recorded as 100/. The per cent 
gain or loss for the same sera stored without Trasylol (hut 
Trasylol added at time of assay) was then calculated. Of the 
15 sera, 13 recorded lower IRG levels when stored without 
Trasylol (mean loss 22^).
/calculation of recovery, the amount of endogenous IHG 
present in the same plasma was subtracted from the total. 
This method assumes identical reactivity of the endogenous 
and the added (beef-pork) glucagon towards the guinea pig 
antibody. When calculated in this manner, recovery varied 
between 80 and 90^ (Table 3)*
(e) The assay of serum and plasma IRG An estimate of the 
precision (s) of the assay when applied to serum was
o 1
determined from the formulas- s = (^ d /2n)^, where"s"is
the standard deviation of the difference"d"between a number
69of duplicate measurements, n . This figure was calculated 
over 2 broad ranges of IRG concentration (representing the 
total of endogenous plus added beef-pork glucagon); it was 
216 ppg./ml. for levels less than I65O ppg./ml. IRG 
(n = 175), erd 409 ppg./ml« for the same range I65O - 3300 
jipg./ml. (n = 43).
The sensitivity was sometimes as low as 20 ppg./250 pi.
(80 ppg./ml.).
The concentration of IRG present in fasting human 
serum was 4OO ppg./ml. + 220 ppg. (S.D) when measured in 
43 specimens of peripheral venous blood from I4 healthy 
young adults (6 male, 8 females).
Discussion The double antibody glucagon assay described above, 
meets/
51
TABLE 3
Recovery of unlabeled beef-pork glucagon added to human 
plasma containing Trasylol.
Exogenous 
glucagon 
added to Net glucagon
250/Wl. Total IRG recovered
plasma measured ( Total less endogenous)
per cent
0 120 (endogenous) — . —
100 200 80 80
500 570 450 90
1,000 990 870 87
2,500 2,210 2,090 84
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/meets the standards of precision, reproducability and stability
during incubation requisite to a valid and sensitive assay. In
addition it offers the advantages of technical efficiency,
adaptation to large scale production and economy which have made
the double antibody technique so widely accepted for the insulin
immunos.ssay, with which it maybe readily coupled within a single
laboratory • ^
The initial problem of producing glucagon antibodies in
adequate titre was overcome by a bi-weekly immunisation schedule.
1 25lodination with I affords a stable yet highly immunoreactive
125tracer substance. Purification of glucagon-I by elution from
a cellulose column provides a labelled hormone which competes in
a consistent and equal manner with unlabelled glucagon, producing
a standard curve which allows the measurement of glucagon in amounts
of less that 100 ppg*
Nevertheless when applied to systems containing plasma or
serum the assay of glucagon presents a problem in its degradation
51by plasma as reported by Mirsky et al . Such degradation 
activity attacks glucagon during incubation. The net result of 
the degradation is a gross magnification of the apparent IRG 
concentration due to diminished immunoprecipitahility of labelled 
hormone as compared withthie relatively intact level among standards 
incubated in the absence of plasma.
Trasylol/
3Trasylol was confirmed as an effective inhibitor of 
1 25glucagon-I degradation. Its place in the measurement of 
plasma glucagon maybe two fold. A major role is the protection 
of labelled and probably unlabelled glucagon during the 24 hour 
incubation with serum or plasma. The amount used must be adequate 
to overcome differing levels of plasma degrading activity in 
various individuals, this quantity being determined as 1000 KIU 
per 250 |il. plasma or serum. Added at an early moment after 
blood withdrawal it may also prevent the destruction of pancreatic 
glucagon which may occur in the presence of clotting at room 
temperature and separation of serum samples. Once exposed to 
Trasylol, the serum or plasma exhibits no further degradation of 
IRG during freezing, storage and thawing.
c H A p T B H 1 
SEGTIOM 2
THE ISOLATED PAMCBBATIO ISLETS OF LAUGEHHAMS 
OF THE HAT
5SUmiAEY
A detailed description of a technique of isolating islets
of Langerhans from rat pancreas using oollagenase is given.
1 25There was no degradation of either glucagon-I or endogenously 
released glucagon in incubation vessels containing pancreatic 
islets when Trasylol was added. Preincubation of islets was 
found necessary before the effect of test substances could be 
tried*
The direct measurement of glucagon release from pancreas 
preparations "in vitro" would enjoy some advantages over "in 
vivo" studies. The experiments could he rapidly and easily 
performed, sensitivity would be less of a, problem than when the 
glucagon molecule is distributed throughout the body spaces, 
mechanisms might be studied, and there would be less chance of 
substances interfering or cross reacting in the immunoassay as 
might occur in blood. In addition glucagon release has never 
been studied "in vitro".
70Because of glucagon degradation the pancreas slice
technique is not applicable unless a method could be devised for
incubsfion of the slices with glucagon antibody similar to that
70recently described by Malaisse et al for insulin. The isolated
71islet technique of Lacy and Kostianovsky seems to be an ideal 
system to study glucagon aud insulin release simultaneously since 
complete removal of the exocrine pancreatic tissue v/ould 
presumably free the systems of degrading enzymes.
MATERIALS M B  METHODS
Animals
All studies were performed on male albino Yfistar rats 
(350“450 gm). The animals were anaesthetised with ether during 
preliminary experiments, but later they were killed by decapitation 
prior to each experiment, since it has been reported that general
72anaesthesia inhibits insulin release .
Incubation media/
/incubation media
The isolated islets were incubated in 1 ml* of a modified
17 g
Krebs Henseleit bicarbonate solution (KHB) with dialysed bovine
serum albumin (Pentex) (2 per cent) added. The buffer was
supplemented with 5 lAI of sodium salts of pyruvic acid, glutamic 
acid and fumaric acid^^*^^. Addition of various concentrations 
of glucose to the buffer were made just prior to each incubation. 
Islet Isolation Procedure
71The islet isolation technique of Lacy and Kostianovsky was 
followed with only a few modifications. Neutral red was not 
used to stain the islets. The rats were stunned by a blow on the 
head and killed by decapitation. The abdomen was opened and the 
common bile duct was 0 annul at ed with P.S. 50 polyethylene tubing’.
The duct vms clamped immediately above the cannulation, and also 
at the entry of the duct into the duodenum, 7“U ml. of Hanks 
solution (a physiological salt solution) was injected to distend the 
acinar tissue. The pancreas was dissected clear of non pancreatic 
material. Two pancreases so dealt with were minced with scissors 
and incubated with oollagenase 35-50 mg. in 5 ml of Hanks 
solution at 37^0. for 6 to 15 minutes with constant stirring.
The amount of oollagenase required varied among the manufacturer's 
lots. The duration of incubation was also variable and depended 
on multiple factors including stirring, pH, the batch of 
collagenese/
D  O
/oollagenase, temperature and probably other factors which could 
not be defined. The incubation period vms extremely critical 
because under-incubation resulted in incomplete separation of 
the islets from the acinar tissue, whereas over-incubation 
caused destruction of the islets. Aliquots of the oollagenase 
incubation were examined periodically under a dissecting 
microscope in order to determine when optimum separation of the 
islets had occurred. This was usually recognised by the 
preparation becoming finely granular, many single acinar cells 
being" seen, and sometimes isolated islets could be noted.
The islets were then separated from the acinar tissue by a 
simple sedimentation procedure. The islets sanlt to the bottom 
leaving the lighter acinar tissue above. The collagenase-treated 
material was first diluted with 25-30 ml. Hanks solution and the 
supernatant, containing predominantly acinar tissue was removed 
after a 3 - 4 minute sedimentation period. This washing procedure 
was repeated for a total of eight times, with the sedimentation 
period progressively shortened to about sixty seconds for the 
last few washes.
In an average preparation 50 islets per rat could be 
isolated but sometimes 100 - 150 islets might be found.
Incubation procedure
After the sedimentation process was completed, the sediment
was/
/was placed in a Petri dish surrounded by crushed ice and examined 
under the dissecting microscope. The free islets were easily 
recognised as round or oval, densely granular objects which were 
quite distinct from the feathery and loose acinar tissue(Figure 11). 
The free islets were then transferred, in groups of ten, with a 
braking pipette*^^ (Figure 12) to individual incubation vessels 
containing 0.95 ml* of iced ÎCHB with 60 mg. per 100 ml. glucose 
and 0.05 ml.(1000 KIU) Trasylol. The flasks were then capped, 
individually gassed for three minutes (95?^  0^ s CO^), and 
preincubated for thirty minutes in a Dubnoff metabolic shaker at 
37^0. Following the preincubation period the buffer was removed 
with a capillary or Pasteur pipette under the dissecting 
microscope and discarded and the islets were washed once with 
0 .9^ NaCl solution, taking care not to remove any of the islets in 
the washing process. At this point, 0.95 nil, of iced KHB 
containing the test substance (i.e. various concentrations of 
glucose) and O.O5 ml. of Trasylol were added to the vessels.
Samples of 0.150-0.250 ml. were removed with a Hamilton pipette 
for determination of baseline glucagon and insulin content (t )^.
The incubation vessels were recapped, gassed, and incubated for 
thirty minutes with constant shaking at 37^0. Again, samples 
were removed for measurement of glucagon and insulin concentrations 
(t^^). In some experiments, in which islets served as their own 
control/
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FIGURE 11
A dark ground photo-micrograph of isolated islets. The 
islets appear oval and densely granular as compared to the 
feathery, loose appearance of acinar tissue#
FIGURE 12
Surg ica l  T u b i n g  
Glass  T u b e
Cork
C a p i l l a r y  T u b e
BraJcing pipette used to transfer the isolated islets to 
the incubation vessels.
/control, the above process was repeated; after a repeat 
preincubation, the islets were incubated with another test 
substance and the hormone production during the second incubation 
compared with that during the first incubation.
Calculation and Expression of Results
The net hormone production during the thirty minute 
incubation period (t^^ - t^) was corrected for dilution and 
expressed, respectively, as the amount of immunoreactive glucagon 
(iRC) and immunoreactive insulin (iRl) released per 10 islets per 
30 minutes. It is realised that the variation in the number of 
cells per islet, and thus the amount of hormone released per islet 
increases the scatter of data when the mean hormone production is 
expressed in terras of a number of islets. Possibly if the results 
were compared in terms of islet weight this variance could be 
minimised somewhat, but because of the minute quantity of tissue 
involved, this form of standardisation of reference was not practical. 
It wan reasoned that the use of ten islets per tube should help 
to decrease any effect of variability in islet size.
RESULTS
Recovery studies
In order to assess the possible need for Trasylol in the
125incubation media to prevent glucagon degradation, glucagon-I
wan incubated with 8 islets in 0 .8 ml,of buffer, with and without
the/
/the addition of 1000 KIU of Trasylol to the media. Aliquots
were removed at 0, 30 and 60 minutes and reacted first with
excess guinea pig glucagon antiserum in order to bind all
125remaining gluoagon-I . The antibody-bound radioactive
hormone mixture was precipitated with excess rabbit antiguinea
pig serum. The mean precipitable radioactivity in eight
incubation vessels was expressed as a percentage of the value at
0 time 4- Standard Error of the Mean (SEM). The mean recovery of 
1 25glucagon-I in 6 to 8 flasks containing Trasylol was 88 4- 1 .2% 
after 30 minutes of incubation, and 81 + 1*5^ * after 60 minutes. 
Without Trasylol, the recovery at 30 minutes was 79 + a 
small but significant difference (p *05), and at 60 minutes 
56 4- 4# (p zL- *001 ). The addition of Trasylol to control 
tubes did not affect the antigen-antibody reaction.
To determine if there was degradation of released endogenous 
hormone in the incubation media, the islets were removed from the 
media after 30 minutes of incubation and the media were incubated 
for an additional 30 minutes. The mean glucagon recovered after 
this additional incubation was 101 4- O.5?" (mean + SHM of 20 
determinations) of the amount present when the islets were removed, 
Trasylol was added to all incubation vessels in a concentration of 
1000 KIU. The insulin recovery under the same conditions was 
99 + 0 .75^ (mean 4- SWi of 7 determinations).
Duration of Incubation and Preincubation 
The/
6 4
/the release of hormone during a preincubation period in 
buffer with 60 mg. per cent glucose is shown in Figure 13» The 
baseline (t^) insulin and glucagon levels before the preincubation 
period were high. The mean insulin level at the end of the 
preincubation period did not change whereas the glucagon level was 
higher, although the difference was not statistically different 
from the t^ value. After changing the buffer and Y/ashing the 
islets once with normal saline solution, the baseline hormone 
levels were much lower and there was significantly greater insulin 
(p Z.,01) and glucagon (p ZL ,05) released at 30 minutes. At 60 
minutes the insulin and glucagon release was not significantly 
greater than at 30 minutes (p Z _ ,01). Therefore, for subsequent 
experiments the islets were preincubated for 30 to 60 minutes in 
60 mg. per cent glucose. They were then incubated for an 
additional 30 minute period in which hormone production was 
measured and the effects of the various test substances compared. 
Discussion
71The isolated pancreatic islet system of Uaoy and Kostianovsky 
has proven to be a satisfactory system to study simultaneously 
factors affecting glucagon and insulin release. There was only a 
small amount of insulin and glucagon degradation in the system, but 
if the proteolytic enzyme inhibitor, Trasylol, was added to the 
incubation media, this degradation could be prevented. Presumably 
Trasylol acts on contaminating proteolytic enzymes of exocrine 
pancreatic/
D b
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vessels.
/pancreatic origin which are incompletely removed during the 
sedimentation and washing process. Alternatively, the islets 
themselves may release proteolytic enzymes*
It is not certain why hormone release from the islets during 
a first or preincubation period was so poor. Presumably the 
islets have been subjected to numerous insults during the 
separation and sedimentation procedures, and they therefore 
require a "rest" period, before they will respond predictably to 
stimuli. The high t^ hormone levels during preincubation might 
represent a rapid, non specific, release of hormone due to damage 
sustained during preparation. However, histology (kindly per­
formed by Dr. Stanley 1. Erlandsen) of isolated islets prepared 
as above showed them to be remarkably free of damage, and the 
granulation of beta cells in freshly isolated islets and in 
preincubated islets was not altered substantially from the 
granulation of islets in pancreases which were fixed immediately 
after death of the animal.
C H A P T E H  2
GLUCAGON IN BLOOD AND TISSUES
C H A P T E R  2 
SECTION 1
DISTRIBUTION OF GLUCAGON IN THE BODY
3 \ m m m
Aoid-alcohol extractions of tissues revealed immunoreactive 
glucagon (IRG) to be present in the pancreas and the alimentary 
tract of 4 species of animal tested, but not in any other tissue 
Ibllowing pancreatectomy in 5 dogs, circulating levels of IRG 
fell only slightly suggesting that circulating IRG was being 
contributed to from an extra pancreatic source, presumably the 
gut*
Although it has long been established that the pancreatic
16 17
A cells are a major source of glucagon ' , it is less certain
whether glucagon is found elsewhere in the tissues. It seems
likely that glucagon however is found in the alimentary tract as
18,19 20 21it has been detected by bioassay and immunoassay methods '
MTHODS
Tissue extractions
Mongrel dogs, male wistar rats, and a squirrel monkey were 
studied. Tissues were taken immediately after death and rapidly 
frozen by dry ice in ethanol. The tissues were homogenised using 
a ground glass homogeniser, and glucagon was then extracted by 
acid ethanol using the method of Kenny^^. Care was talcen to 
prevent degradation of glucagon by keeping all extraction 
processes at or ice temperature. The final extract was
lypholised, stored at -20^0. and reconstituted in veronal buffer, 
pH 8.1 for assay.
The single human subject was a 24 year old man, in apparent 
good health, killed as a result of an automobile accident. His 
organs were removed one hour after death.
"In vivo" studies
Mongrel dogs were anaesthetised by barbiturate and venous 
catheters inserted at laparotomy into a peripheral vein, a large 
jejunal/
/jejunal vein, and the pancreatic-duodenal vein.
RESULTS
Table 1 shows the amount of immunereactive glucagon (IRC)in 
the tissues. Results are expressed in mpg. of IRC per gm. of 
wet organ. Large amounts of IRC were present in the pancreas of 
all species of animals. Smaller amounts of IRC were present in 
the alimentary tract, although none was found in the stomach or 
duodenum (one dog only tested here). A rather surprising finding 
was the presence of IRC in the colon and even in the rectum.
The concentration of IRC in the pancreas was greater than that in 
the gut, but when the size of the alimentary tract is considered, 
then the total amount of IRC in the intestine may equal that in 
the pancreas.
The result of pancreatectomy on circulating IRC levels is 
shown in Figure 1. Following pancreatectomy in 5 dogs peripheral 
vein levels of immunoreactive insulin (IRI) fell from a mean of 
21 p units/ml. to 5 p units/ml. in 30 minutes. Plasma glucose 
levels rose from a mean of 110 mg./lOO ml. to 163 mg./lOO ml. in 
90 minutes. IRC levels measured in both a peripheral vein and 
a jejunal vein showed only a very slight fall. This suggests that 
a large amount of circulating IRC is made up from extra pancreatic 
sources presumably enteric in origin. Figure 2 shows the 
results of a more extensive experiment on a single dog.
In/
TABLE 1
InuTLunoreactivG Glucagon in Tissues,
oi/ig/g wet organ
Human Dog Monkey Rat
Pancreas ' 3700 (1) 2200 (3) 2500 (1) 275 (6)
Stomach — 0 (2) —
Duodenum — 0(2) -  1
Jejunum 290 (1) 43 (3) - 44(3)
Ileum — -  J
Colon
Eeetum 120 (1)
99 (2)
=  } 58 (3)
Adrenal — 0 (1) .—
Kidney — 0 (2) — 0 (1)
Liver '— 0 (1) .— 0 (1)
Spleen — — ' 0 (1)
Heart — . — 0 (1)
Diaphragm — . — '— — 0 (1)
Thymus — —' — 0 (1)
No. of organs assayed is shown in parentheses.
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Following panoreateotomy in 5 dogs under barbiturate 
anaesthesia, there was a sharp fall in circulating IRI levels 
and a rise in plasma glucose levels. IRGt levels in peripheral 
and jejunal veins changed little however.
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In a single dog colonic vein and jejunal vein, IRG levels were 
similar to pancreatic vein IRG levels. Following pancreatectomy 
circulating IRG although falling did not disappear. When the 
small bowel and stomach were removed, circulating IRG levels 
virtually fell to zero.
/in this dog, catheters were inserted into a jejunal, a colonic, 
a pancreatic and a peripheral vein. It is interesting to note 
that jejunal and colonic vein IRG levels in the intact animal 
were at least equal to pancreatic vein levels. This particular 
dog was unusual in this respect, for as will be shown in later 
parts of this thesis, pancreatic vein levels usually exceeded 
jejunal vein levels in the basal state. Following pancreatectomy 
there was a fall in the IRG levels in colonic, jejunal and 
peripheral veins but there still remained measurable levels of 
IRG. It was not until the stomach and small bowel were also 
removed that circulating levels of IRG virtually reached zero. 
Removal of the colon had no further effect. The experiment 
suggests that the gut contributes IRG to the circulation. 
Discussion
The results strongly suggest that circulating IRG is a 
product of both the pancreas and the gut. The gut seems to 
contribute not only from the small bowel but from the large bowel 
too. Unless experiments are so designed to mea.sure secretion 
of IRG from different sites of the body (multiple venous catheters 
or the pancreatectomised animal) there is no way of distinguish­
ing the relative contribution to circulating IRG from the pancreas 
and from the gut. The fact that there is a material in the bowel 
which cross reacts with glucagon antibody, gives no assurance that 
the cross reacting material is identical with standard pancreatic 
glucagon/
76
/glucagon. It might only mean that part of the molecule is 
similar in that it reacts with antibody. For future reference 
therefore it would be better to consider the gut material as 
gut immunoreactive glucagon (GIRG) to distinguish it from 
pancreatic immunoreactive glucagon (PIRG).
C H A P T E R
SEOTIOH 2
WHOLE BODY AND LIVER CLEARANCE
STUDIES OP GLUCAGON
smmÆï
The half life for beef-pork glucagon in the intact dog 
was 3o5 minutes. In the isolated perfused rat liver the 
biological half life for pork immunoassayable insulin was 
determined to be 17 minutes» The corresponding figures for 
beef“pork, rat pancreatic and rat gut immunoassayable glucagon 
were 19> 23 and 27 minutes respectively. The data are in keeping 
with the liver being a major site for the degradation of insulin 
and glucagon.
Samols et al (1966)^^ quote a half life of 10 minutes for 
glucagon in the circulation of man. The half life of a hormonal 
substance such as glucagon is a product of two factorss
(1) its distribution within the body spaces, and
(2) its clearance or removal by specific tissues or organs.
The liver is often quoted as a major site for the degradation of 
78 7 9
glucagon . However the evidence for this is only indirect,
131 54-inoluding destruction of I glucagon by liver homogenates ,
53loss of hyperglycaemic properties of insulin after liver perfusion ,
and trans hepatic gradients in glucagon levels in the intact
a n i m a l T h e  introduction of the immunoassay technique now
allows a more direct appraisal of the situation.
In addition because of the finding of immunoreactive
glucagon (IRG) in both pancreas (PIRG) and gut (GIRG), an attempt
was made to compare the clearances of these two substances.
Experiments were designed to study the whole body clearance of
IRG, The clearance of PIRG and GIRG in the liver perfusion
system W8,s also studied. Because of the already well es tab-
81
lished hepatic clearance of insulin , this hormone was also studied 
concomitantly to provide a comparison for the glucagon values 
obtained,
mTHQDS M B  1IATERIAL5 
For the whole body clearances two mongrel dogs were 
anaesthetised/
/anaesthetised by barbiturate, and catheters inserted into the 
portal, hepatic and peripheral veins. Crystalline beef-pork 
glucagon was infused into the superior mesenteric vein at a 
constant rate of *38 pg./minute for 10 minutes using a constant 
infusion pump. Bloods from portal, hepatic and peripheral sites 
were withdrawn simultaneously during the infusion and following 
cessation of the infusion.
Intact livers weighing 14-15 gm. from male Wistar rats
(450 gm.) fed ad libitum, were perfused cyclically according to
82the method of Miller et al . Because haemolysis from red cells 
in the perfusion system was found to interfere with the immuno­
assay systems for insulin and glucagon, the medium used consisted 
of Krebs-Ringer bicarbonate buffer, pH 7,4 , containing 100 mg. of 
glucose and 1 gm. of albumin per 100 ml. The total perfusate 
volume was 60 ml. Blood flow through the liver was maintained 
at 35-40 ml./min. and the perfusions were terminated after one 
hour. Sampling was done from the hepatic effluent and not more 
than 10 ml. (l2^) were removed during any single perfusion.
Acid-aloohol extracts of rat gut (jejunum and colon) and of 
rat pancreas were prepared according to the method of Kenny^^.
The gut extracts contained 8 mjag. IRG equivalents and 20 units 
immunoreactive insulin (iRl) per mg. of lypholised weight; the 
pancreatic extracts had 20 m/ig. IRG and 10,000 IRI per mg.
After/
/After a 10 minute control perfusion period, the material 
to be tested was added to the perfusate, and samples were taken 
over an hour period. PIRG was added in tv/o formss-
(1) crystalline beef»pork IRG (1.2 jug.) (Eli Lilly), and
(2) rat PIRG O .4 ug, IRG in 20 mg. extract.
GIRG was added as the rat gut extract (0 .4 MS» IRG equivalents
in 50 mg. extract). Measurements of IRG were made following the
injection of rat pancreatic extract. Simultaneous with the rat
GIRG clearances, pork insulin (Eli Lilly) (50,000 ja units added)
clearances were measured in the same perfusions.
The results were plotted as per cent of maximal (initial)
concentration determined 6 minutes after the insulin or glucagon
12had been added to the bath, when complete mixing had occurred 
From semi-logarithmic plots of this data, the half lives (t ^) of 
IRI and IRG in this system were estimated from the linear portion 
of the graph. No correction was made for the error introduced 
by the decreasing perfusate volume as this did not exceed 12)^ .
RESULTS
Glucagon infusion into 2 dogs
The results of this experiment are shown in Figure 3» The 
t for glucagon in the 2 dogs was 3 and 4 minutes respectively 
which gives a mean value of 3-5 minutes. Portal vein levels were 
higher than hepatic, and hepatic vein levels higher than peripheral 
vein/
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0.38 pg/minute of beef-pork gluoagon was infused constantly into 
the portal vein of 2 dogs. Portal vein levels are higher than 
hepatic suggesting liver clearance of the hormone. The t for 
gluoagon in the 2 dogs was 3 and 4 minutes respectively.
FT
Ô
/vein levels. The portai-hepatic gradient suggests liver 
clearance of the hormone, but complex blood flow factors complicate 
the analysis. The portal-peripheral gradient will be partly due 
at least to dilution effects.
Isolated liver perfusion
The data for all hormone clearances are presented in Table 2, 
and IRG clearances are also shown graphically in Figure 4* The 
t -g- values in Table 2 are expressed as mean + S,D, of the t -|- 
for each individual experiment performed for that hormone. The 
t values in Figure 4 are calculated from the single mean graph 
of all experiments for the hormone. The 2 methods give fairly 
similar results. The t -g values referred to below are those 
which appear in Table 2, Clearance was mainly by first order 
kinetics, but there was a tendency for a slower phase of clearance 
to appear later. For all clearances, the Initial linear phase of 
the logarithmic plot was used to calculate the t -g-.
The t-^  for crystalline beef-pork IRG was 19 -i- 2.4 min.
(mean h* S,D,) (Figure 4)* The clearances of rat PIRG and rat 
GIRG are shov/n in Figure 4? end are similar, 23 + 3,6 and 
27 + 9*3 minutes, respectively. Pork IRI had a t -g- of 17 f 4»2 
minutes. There were no statistically significant differences 
between any of the clearances.
The hepatic clearances (k) of the hormones were also 
calculated/
FIGURE 4
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Hepatic clearance of crystalline beef-pork glucagon (upper 
figure), and rat gut gluoagon and rat pancreatic glucagon 
(lower figure)are plotted as the percentage of the maximum 
(initial) concentration of immunoreactive glucagon.
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V/calculated from the formula (a ) of Mortimore et al^^ and Burgi 
et al^^.
(A) k " 2.3 X V X Log Ga 
A  t ' Of
where k ~ hepatic clearance of reaction velocity constant.
V = volume of perfusion fluid during ss.mpling time ^  t.
Ca ~ hormone concentration at beginning of time interval /^  t.
Cf hormone concentration at end of time interval t.
The k values for pork IRI, beef-pork I.RG, rat PIRG and rat
GIRG are shov/n in Table 3*
Discussion
The t-J- for pork IRI of 17 minutes in the liver perfusion
system agrees well with the figure of 14 minutes obtained by 
61
Solomon et al , using the identical liver perfusion technique in
the same laboratory as the author, but using a red cell containing
media as the perfusate. This would appear to indicate that the
substitution of albumin buffer in the system still results in a
liver perfusion system adequate for hormone clearance studies.
Our data for gluca,gon clearance in the liver confirm previous 
64 63 86reports suggesting that the liver is a major source of
glucagon degradation. Several workers have, however, suggested
that glucagon may be cleared more rapidly by the liver than 
64 86
insulin ’ , but there was no evidence from the results in the
present report that this was the case.
Based/
TABLE 3
HEPATIC CLEARANCE OF GLUCAGOH OF TARIQïïS 
SPECIES AHB TISSUES
Hormone Beef-pork Hat Rat Pork
IRC PIRG GIRG IRI
k(hepatic clearance
ml/min ) 2.91 2.4O 2.O4 3.24
For definition of k see text.
o/Based on the assumption that hepatic inactivation is
primarily responsible for clearance of these hormones in the
intact rat, a theoretical t for glucagon can be calculated
87using the approximation of Farris and Griffith and formula B
of Burgi et al^^. By calculation this value is 5.1 minutes for
beef-pork IRG, 6.2 minutes for rat PIRG, and 7*3 minutes for rat
GIRG. These approximate values are a little lower than the
7 7
estimated t -J - for glucagon in man of 10 minutes . However the
values are somewhat greater than the t t values for glucagon of
3 and 4 minutes respectively in the intact dogs. The shorter
half life in the dogs was presumably partly caused by the large
distribution volume into which the rather small molecule of
gluoagon would go.
65Unger et al* postulated that IRG extractable from the
gu.t differs from pancreatic IRG, The similar clearances of
the two materials which v/e obtained in these studies, at least
suggest identical handling by the liver. The rapid clearance
by the liver is in keeping with the quick rise and fall in
66concentration noted in GIRG after oral glucose .
C H A P T E R  2
SECTIQH 3
IMMUNOLOGICAL STUDIES OF GLUCAGON
SUIvmKY
Immunological studies of different species of glucagon 
showed immunological identity among heef-pork, rat, dog, 
human and monkey pancreatic glucagons. However dog pancreatic 
extract was different from dog jejunal extract and human 
pancreatic extract differed from human jejunal hut resembled 
human rectal extract. It is suggested that jejunal glucagon 
may differ immunologically from pancreatic glucagon*
1Antibodies raised against a hormone of one species will 
often react differently with the hormone of another species due 
to slight differences in the physico-chemical structure of the 
hormone among different species. Insulin has been studied most
in this respect. Among 11 insulins from 10 different mammalian
• 88 , „ . 88 . 89  ^  ^ 90,91species only those from dog , pig and sperm whale
contain identical amino acid sequences, the others being
distinguished by differences in one or more residues. Yet all
possess essentially identical hormonal potency in all species
tested. If antibodies are raised for example against species A
insulin some may react very similarly with species A and species
B insulin, but others, known as discriminating antibodies will
react very differently with species A insulin as compared with
species B» The use of a discriminating antibody allowed Samols 
92and Ryder to differentiate exogenously administered beef insulin 
from endogenous insulin in human subjects.
65
Hunter and Greenwood described tests of parallelism where 
it could be calculated whether hormones or unknowns reacted 
similarly with respect to antibody. If the substances inhibited 
the reaction between labelled hormone and the antibody v/ith 
parallel stops then it could be assumed the substances were 
immunologically indistinguishable.
Although the chemical structure of glucagon has been 
described^/
92
/described"* possible variations in structure amongst species have 
not been studied in the same way as insulin. It thus seemed of 
interest to test under immunoassay techniques, whether glucagons 
from different species showed differences in their immunological 
behaviour. In addition it seemed also pertinent to study the 
immunological behaviour of pancreatic glucagon as compared with 
gut glucagon.
Methods and materials
Tissue extracts from mongx*el dogs, male wistar rats, a 
squirrel monlcey, and a human subject were studied. Tissues were 
extracted by the method of Kenny*^  ^which has been described 
elsewhere (Chapter 2, Section 1).
Results
Two antibodies were used in the studies - antibody A and 
antibody B. The results with antibody A (used at a final dilution 
of 1s1875) G,re shown in Figures 5 and 6. Close parallelism 
existed among all the pancreas extracts - monkey, human, rat, dog 
and the beef-pork gluca,gon standard. However, although human rectal 
extracts were parallel with the human pancreatic extracts, the 
human jejuanl extracts were shallower than the human pancreas 
(pZ-»Ol). Similarly dog jejunal extracts were shallower than 
dog pancreatic extracts (pZ^.Ol). Rat pancreatic extracts, 
however, were not distinguishable from rat small and large gut 
extracts/
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Tests of parallelism among organ extracts. All pancreatic 
extracts were parallel mth one another, but human pancreatic 
extract and dog pancreatic extract were not parallel with their 
respective jejunal extracts (p *0l). Human rectal extract 
was parallel, however, with human pancreatic extract. (Antibody 
A used in studies).
FIGURE 6
INHIBITION SLOPES FOR GLUCAGON IN RAT ORGAN EXTRACTS
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Tests of parallelism among rat organ extracts. No 
immunological differences were found among rat small and large 
gut extracts, rat pancreatic extract and beef-pork glucagon 
standard. (Antibody A used in studies).
/extracts respectively^ and all showed parallelism with the beef- 
pork glucagon standard.
Glucagon antibody B (final dilution Is4500) showed no 
discrimination among human jejunum, human rectum., a concentrated 
acid-aloohol extract of human serum, human pancreas, and beef-pork 
glucagon standard (Figure 7)* Similarly this antibody was unable 
to discriminate among beef-pork standard, rat gut extract and 
rat pancreatic extract (Figure 8),
Discussion
These studies suggest that although there appears to be close 
immunological similarity amongst the pancreatic glucagons of 
several species of animals, there might be inununological differ­
ences in the glucagons found in the pancreas and gut. The use 
of an antiserum which does not discriminate between pancreatic 
glucagons of various species and the beef-pork standard glucagon 
has the advantage that the reading of unlmowns gives results in 
actual glucagon content.
These results showiuig non parallelism between jejunal and
21
pancreatic extracts agree with those of Samols et al and 
22Sohopman et al . In addition both of these authors found perfect 
parallelism between pancreatic and colonic extracts as did this 
study. A discriminating antibody is therefore able to detect an 
immunological difference between small gut glucagon and pancreatic 
glucagon/.
FIGURE 7
Human
rectum
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serum
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je junum
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25^ 100 400
Human 
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100 400________
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Glucagon antibody B did not discriminate among extracts 
of human jejunum, rectum, pancreas and serum, and the beef* 
pork glucagon standard.
FIGURE 8
GLUCAGON INHIBITION SLOPES
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Volume of extract (^ 1 ) yu./i.g
Glucagon antibody B did not discriminate between extracts 
of rat pancreas and gut and the beef-pork standard.
/glucagon. I'his may suggest that gut glucagon is a different 
substance from pancreatic glucagon, V^y colonic glucagon rather 
than jejunal glucagon should more resemble pancreatic glucagon is 
impossible to answeb. It remains possible, however, that during 
the preparation of these acid alcohol extracts of tissues that 
damage may occur in their preparation to malce results of the above 
studies misleading. Hovfever, independently 3 groups of workers, 
including the author, have obtained similar results.
C H A P T E R  2
SECTION 4
GLHCAGOK AND INSULIN IN BILE
SÜIMARY
lïïununoreactive insulin and iimnunoreaotive glucagon were 
detected in bile, the hormone levels in bile corresponding with 
blood levels. It is suggested that the bile may form an 
excretory route for these hormones.
Bile has been reported to serve as an excretory route for 
170 171insulin , and therefore it was decided to study bile for
the possible presence of glucagon.
METHODS AND MATERIALS
The experimental model was identical to the one described 
in greater detail in Chapter 3, section 3 of this thesis.
In 3 anaesthetised mongrel dogs (20-30 kg.), a catheter 
was passed into the common hepatic duct, and the bile collected 
for 10 minute periods. Hormone levels in bile are expressed 
per 10 minute volumes of bile. Catheters were also passed into 
the cranial pancreatico-duodenal vein, and a peripheral vein.
Bile was stored frozen for assay of immunoreactive glucagon 
(iRCj and immunoreactive insulin (iRl).
The secretin and pancreozymin used in the experiments were 
identical to those described in Chapter 3, section 3 of this thesis.
RESULTS
65
IRI and IRC were detected in bile and inhibition slopes of 
IRI and IRC (Figures 9  and 10, respectively) in bile indicated 
close parallelism with standard hormones.
During a secretin-pancreozymin infusion, bile levels of 
IRC (Table 4) and IRI (Table 5) were recorded. The results are 
graphically represented in Figure 11. The changes in blood levels 
of IRI and IRC are fully described in Chapter 3, section 3, and 
will/
FIGÏÏRE 9
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Serial dilutions of bile (on left) showed parallelism with 
standard canine insulin.
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Serial dilutions of bile (on left) showed parallelism with 
standard beef-pork glucagon.
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Coniparison of Uile and Ulood liorniono levels in 3 dogs during 
seoretin pancreozymin infusion*
/will not be disoussed in detail here. Levels of IRI in bile 
increased in all 3 dogs during the first or second 10 minute bile 
collection period following the pancreozymin infusion, and were 
concomitant with the rise of the hormones in the blood* The 
IRG levels in bile after pancreozymin were more variable in 2 
dogs. In one dog ( R o . 2 2 ) ,  however, there was an unexplained 
enormous rise of both IRI and IRG in bile during the 30-40 
minute collection period following pancreozymin. Follov/ing 
pancreatectomy there was a fall in the levels of both hormones 
in bile (Figure 12).
DISCUSSION
We have confirmed the previous reports of the presence of 
IRI in bile^^^*^^^, and now find that IRG can also be detected 
in bile. As the liver is an important site for the degradation 
of glucagon (Chapter 2, section 2), it is not surprising that it 
should be found in bile. Bile insulin levels tended to be
172
correlated with blood levels as noted by Lopez-Quijada et al 
The fall in hormone levels in bile following pancreatectomy is 
consistent with the removal of the only source of IRI and one 
source of IRG. Presumably bile acts as an excretory route for 
these hormones.
It might be suggested that the bile may be a source of the
IRG/
FIGURE 12
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Following pancreatectomy, there was a fall in IRG and IRI 
excretion into bile.
/IRG present in the gut. However, the author was unable to 
. detect any difference in the amount of IRG in the gut when the 
bile ducts were ligated in rats for 3 days.
C H A P  T _ E R 30 :1" IIIIM r w * *i*i i„P' nwii m ##%* rfmiriinPi laii i ,m, irfSS*
FACTOHS APFECTIHG THE RELEASE OF GLUCAGON
G H A P T S R  3 
SECTION 1
GLUCOSE CONCENTRATION AND GLUCAGON RELEASE
SIHMARY
Moderate hypoglycaemia (insulin induced) and smaller falls 
in blood glucose (tolbutamide induced) were equally effective in 
increasing pancreatic IRG secretion in laparotomised dogs under 
barbiturate anaesthesia. Hyp0rg'lyc8.emia inhibited pancreatic 
IRG secretion. Changes in IRG levels in peripheral and jejunal 
veins during hypoglycaemia were unremarkable. In the 
pancreateotomised dog no change in IRG secretion from the 
jejunum was noted. During the tolbutamide experiments slight 
rises in IRI secretion were related to rises in pancreatic IRG 
secretion. A rise in serum IRG was demonstrated in conscious 
dogs after oral glucose. A marked rise in serum IRG occurred 
after intrajejunal glucose in pancreateotomised dogs, suggesting 
its enteric source.
In the isolated islets of Langerhans of the rat, the results 
were consistent with the "in vivo" findings in the dog. Glucose 
exerted an opposite effect on insulin and glucagon release. As 
the glucose concentration in the incubation media was raised from 
30 to 300 mg. per 100 ml., there was a decreased secretion of IRG 
and an increased secretion of IRI. The addition of 2-deoxyglucose 
to the media inhibited IRI release but had no effect on IRG,
It is concluded that hypoglycaemia is a stimulus, and 
hyperglyoaemia is an inhibitor, of pancreatic IRG secretion but 
a/
115
/a changing blood glucose concentration has no effect on enteric IHG 
secretion. Enteric IRG is stimulated by oral glucose and an 
insulinogenic role for enteric IRG is considered.
114
The classical experiments of Foa and associates^ 
appeared to establish the function of glucagon as a hormone of
2glucose need through its established actions of glycogenolysis
and gluconeogenesis^. The advent of the immunoassay for
glucagon^ made possible the direct measurement of glucagon
during hypoglycaemic states and Unger et al showed an increase
in glucagon secretion when the blood glucose concentration fell.
Thereafter, however, difficulties with the assay were reported,
principally involving the degrading effect of serum on labelled
glucagon within the assay, which necessitated the addition of
Trasylol (Bayer Ltd*), a proteinase inhibitor, to the assay tubes^5
The finding, too, of a material in the gut which cross-reacted
20 21with glucagon antibody ' , and which contributed to circulating
glucagon levels, confused the measurement of glucagon in 
peripheral blood. In addition, the reports of the insulin- 
stimulating properties of gluoagon^^'^^'^^ have tended to conflict 
with the classical role of glucagon in providing glucose. 
Consequently, it v/as decided to reassess the effect of blood 
glucose concentration on glucagon secretion from both the pancreas 
and the gut.
MATERIALS M B  MTHQBS 
The studies were performed on overnight-fasted mongrel dogs 
(20-30 leg.) under barbiturate anaesthesia. Catheters were passed 
through an abdominal incision into the cranial pancreaticoduodenal 
vein, a large jejunal vein, and into a peripheral vein. Care was 
taken/
11
/taken not to obstruct the pancreatic vein during the experiments 
and best results were obtained with a 21 guage thin-walled needle 
inserted in the direction of blood flow. At the time of blood 
sampling, the pancreatic vein at its entry into the portal vein 
was occluded with a simple thread snare to prevent reflux from 
the portal vein.
Experiments were also performed on isolated pancreatic islets 
of Langerhans from male wistar rats (350-450 gm.) prepared as 
described elsewhere (Chapter 1, section 2),
HSSTJLTS
Insulin Infusions
The effect of insulin induced hypoglycaemia on immunoreactive 
glucagon (IRG) release is shown in Figure 1. Insulin was injected 
rapidly (O.5-0*7 units beef-pork regular insulin/kg,) into a 
peripheral vein in 5 dogs. Fuller details, including individual 
pancreatic IRG, peripheral vein plasma glucose values, and the 
mean value for jejunal and peripheral vein IRG levels are 
presented in Table 1. Pancreatic vein IRG began to rise 
concomitantly with the fall in plasma glucose, and the rise was 
significant by the paired t-test at 40 and 50 minutes after the 
insulin injection (p .05, kl.05 respectively). A first 
peak in the IRG secretion occurred at 40 minutes which coincided 
with the nadir of the plasma glucose values. In 3 of the dogs 
rises/
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FIGURE 1
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Hypoglyoaemia was induced in 5 dogs by insulin (0*5 - 0.7 U/kg.) 
injected into a peripheral vein. The asterisks represent 
statistically significant rises in mean pancreatic IRG levels 
over basal.
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/rises in plasma glucose followed shortly after the peaks of 
pancreatic vein IRG (dogs 28 - 30). Dog 27 had modest falls in 
plasma glucose following the insulin^ and in this dog the lowest 
plasma glucose values were not recorded until 90 minutes when 
pancreatic vein IRG began to rise. IRG levels were higher in 
the pancreatic vein, in both basal and hypoglycaemic states, than 
in the jejunal or peripheral veins which both showed similar 
values (Table 1). The hypoglycaemia did not influence plasma 
IRG levels in either peripheral or jejunal veins.
At the conclusion of the above experiments a pancreatectomy 
was performed in the same 5 animals, and the same dose of insulin 
as before pancreatectomy was rapidly injected into a peripheral 
vein. Despite much greater hypoglycaemia than in the intact 
animal, IRG levels in a jejunal vein remained unchanged 
(Figure 2). There was also no tendency for the plasma glucose to 
rise again after it had reached its nadir a,t 40 minutes. 
Tolbutamide Infusion
The production of profound hypoglycaemia by massive doses 
of insulin can scarcely be described as physiological; such 
doses may possibly depress glucagon secretion. Therefore, the 
effect on IRG secretion of milder falls in circulating glucose 
concentration was assessed in 4 dogs, using tolbuta,mide. It
also provided an opportunity to correlate endogenous IRG 
and/
FIGÏÏiaS 2
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Following panoreatectoray in 5 dogs, insulin (0.5 » 0.'/ u/kg. ) 
induced hypoglycaemia had no effect on mean IRO levels in a 
jejunal vein.
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/and immunoreaotive insulin (iRl) release. Tolbutamide 1 
was given over one minute into a peripheral vein» The results 
are shovm in Table 2, and include individual values for the dogs 
for IRQ in the pancreatic vein, IRI and plasma glucose in a 
peripheral vein, and the mean IRQ- values for jejunal and 
peripheral veins. Pancreatic vein IRG levels in relationship 
to peripheral vein IRI and glucose values are illustrated in 
Figure 3.
Following the tolbutamide injection, there was only a modest 
rise in peripheral IRI levels associated with a gradual descent of 
the plasma glucose. The general anaesthesia may have rendered 
the dogs tolbutamide resistant. Pancreatic IRG levels began to 
rise 20 30 minutes after the tolbutamide, and this was
significant at 40, 50, 70 and 80 minutes (p Z. .05, Z, .0 5, zL. .0 5,
.01 respectively). The IRG levels peaked initially at 50 
minutes and then again at 80 minutes. It is noteworthy that 
associated with the rise in IRG levels, there appeared to be a 
slight rise in peripheral vein IRI levels in 3 dogs (dogs 32, 33, 
35)' As in the insulin studies, changes in the jejunal and 
peripheral veins were less than that observed in the pancreatic 
vein, although inconsistent and insignificant rises in the jejunal 
vein levels occurred between 20 and 50 minutes following 
tolbutamide/
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TOLBUTAMIDE INDUCED HYPOGLYCEMIA IN DOGS
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Tolbutamide, 1 gm*, was injected into a peripheral vein. 
Significant rises in pancreatic IRG levels over basal are 
represented by asterisks. Each point represents the mean 
of 4 dogs.
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/tolbutamide (Table 2).
Glucose Infusion
In the same 4 dogs, two hours after tolbutamide, 25 gm. of 
glucose was infused over 4 minutes* At this time pancreatic 
IRG levels were still elevated over the basal in all 4 dogs.
The ensuing hyperglycaemia resulted in a rise in IRI secretion 
but a fall in pancreatic vein IRG secretion (p «05 at 2 minutes 
after glucose), although IRG levels rose markedly in 1 dog 
(dog 36) at 50 and 60 minutes after the glucose. The levels, 
however, remained depressed in the other 3 dogs (Table 3 and 
Figure 4)*
Effect of oral glucose
Following oral glucose, 2 gm./kg. body weight, portal vein 
IRG rose significantly in conscious dogs (Figure 5)* After 
pancreatectomy in two anaesthetised dogs (Figure 6) serum IRI 
fell to near zero, and did not rise after 50 gm. intrajejunal 
glucose. Serum IRG fell only slightly in a periperhal vein 
following pancreatectomy but not at all in the portal vein 
(Figure 7). Following intrajejunal glucose, there was a 
dramatic rise in IRG in both dogs (Figure 7), which’was greater 
than that seen in the intact conscious dog. Prior to pancrea­
tectomy the highest levels of serum IRI and IRG were recorded in 
the pancreatic vein. There was a distinct portal-peripheral 
vein IRl/
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glucose is illustrated.
FIGÏÏHS 5
Oral Glucose Feeding in Dogs(n= 
(2G /Kg body weight)
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Oral glucose feeding (2 gm./kg. body weight) in 11 dogs 
resulted in a significant increase in portal vein serum 
glucagon (p Z. ,02).
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Serum Glucagon Levels in 2 Poncreatectom ized Dogs
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Seruin glucagon fell only slightly in a peripheral vein following 
pancreatectomy in 2 anaesthetised dogs. Following intrajejunal 
glucose, there was a dramatic rise in IRG- in both dogs.
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/vein IRI gradient, but no portal-peripheral vein IRG gradient.
Following intrajejunal glucose, the level of IRG in the portal
vein, which in the dog drains the gastrointestinal tract apart
from the anal canal, was higher than in the superior mesenteric
vein which drains only the jejunum and ileum.
Sffect of glucose concentration on IRI and IRG release from 
isolated islets__________________ ____ _______ _
The effects of various glucose concentrations on hormone 
release are compared in Figure 8. IRI release was augmented 
by increasing the glucose from 30 to 300 rag. per 100 ml. IRG 
release (mean -h S.S.M.), however, was greatest at a glucose 
concentration of 30 mg, per 100 ml•(1.53 + 0.28 mpg./lO islets/
30 rain.), and the output was diminished by increasing the glucose 
concentration to 150 mg, per 100 ml.(1.06 + 0.13 mpg./lO islets/
30 rain.), although this difference did not achieve statistical 
significance ( p ^  .01). There was a slight further decrease 
in the IRG release when the glucose concentration was raised to 
300 mg. per 100 ml.(0.78 -f 0,12 mpg./lO islets/30 rains.) and this 
amount was significantly less than that produced with 30 mg, per 
100 ml. glucose (p .02). Thus the effect of glucose concentrat­
ion on IRI release is opposite to its effect on IRG release.
Effect of glycolytic block on IRI and IRG release from islets
It is known that 2-deoxyglucose and mannoheptulose, both 
incompletely metabolisable sugars, will block the release of 
insulin/
FIGURE 8
ISO
EFFECT OF GLUCOSE CONCENTRATION ON 
INSULIN AND GLUCAGON RELEASE
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The effect of glucose concentration on insulin and glucagon 
release. The net hormone production during 30 minute incubations 
in various glucose concentrations is compared. Each incubation 
was preceded by a 1 hour preincubation in 60 mg. per 100 ml. 
glucose. Results are expressed mean +
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/insulin in response to a glucose stimulation^^. To determine 
the effect of these sugars on glucagon release, islets were 
incubated with I50 mg. per 100 ml. glucose and the IRI and IRG 
response compared to other islets incubated with 2-deoxyglucose 
(150 mg.per 100 ml.) or mannoheptulose (15O mg. per 100 ml.) plus 
150 mg. per 100 ml. glucose. As seen in Figure 9 the addition 
of nonmetabolisable sugars had no effect on IRG release but 
caused the expected inhibition of IRI release.
DISCUSSION
Both the isolated islet studies and the dog studies confirm
57the "in vivo" findings of Unger et al of a rise in pancreatic 
vein IRG during insulin induced hypoglycaeraia. Certain quanti­
tative differences, however, exist between the data of Unger et 
57al , and the present results, Unger et al showed a slow steady
rise in pancreatic IRG which did not become significant until 2
hours after the insulin infusion, and was still rising at 3 hours,
v/hereas this study shows peak levels which coincide with the nadir
of the glucose values at 40 minutes, and thereafter there was no
significant further increase. The negative effects of
95hypoglycaemia on IRG secretion reported by Lawrence and Samols
96
et al are probably due to the fact that peripheral blood 
measurements of IRG were made in their studies. In the present 
study/
1FIGURE 9
EFFECT OF GLYCOLYTIC BLOCK ON 
NSULIN AND GLUCAGON RELEASE
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The effect of glycolytic block on insulin and glucagon release. 
After an initial preinoubation for one hour in 60 mg. per 100 
ml. glucose, a comparison was made between the net hormone 
production from islets subsequently incubated for thirty minutes 
in 150 mg. per 100 ml. glucose, I50 mg. per 100 ml, glucose + I50 
mg. per 100 ml. 2-deoxyglucose, and I50 mg. per 100 ml. glucose + 
150 mg, per 100 ml. mannoheptulose. The results are expressed as 
mean + SM.
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/study no changes in peripheral vein levels of IRO occurred despite
a rise in pancreatic vein levels.
It is of interest that a slight fall in plasma glucose produced
by tolbutamide was equally as effective in promoting pancreatic IRG
secretion as the greater degree of hypoglycaemia produced by large
doses of insulin. The study has confirmed too the report by linger 
57et al that hyperglyoaemia depresses pancreatic IRG secretion.
It might be postulated that glucagon sensitively responds to small
changes in circulating glucose concentration, being stimulated by
small falls, and inhibited by rising levels, and so producing
blood glucose homeostasis. The data are consistent with glucagon
as a hormone of glucose need as originally proposed by Foa and
co-workers^^*^^*^^ and with the established glycogenolytic^ and
gluconeogenic^ properties of glucagon.
In these experiments no effect of hypoglycaemia on the
secretion of IRG from the jejunum was detected, and the results
are similar to the effects of pancreozymin on pancreatic and gut 
55IRG secretion . This would be in agreement with the observation 
2 3of Unger et al who were unable to show glycogenolytic effects 
in a liver perfusion system of IRG extracted from the gut.
The finding of a rise in IRG after intrajejunal glucose in
23
pancreatectomised dogs confirms Unger et al*s finding that the 
glucagon rise after oral glucose is enteric in origin in dogs, but 
is/
/ 21/is contradictory to Samols et al’s findings in man. Because 
of the much higher level of IRG after glucose in the portal vein 
than in the superior mesenteric vein, it appears that the colon 
and/or rectum may contribute to the rise in IRG seen after oral 
glucose. It is interesting to speculate as to what the role of 
intestinal IRG may be. The rise of circulating gut IRG after 
oral glucose would certainly be consistent with an insulin 
stimulating role. It was interesting to note that in the 
experiments in the pancreatectomised dog, the rise in gut IRG 
was more dramatic than in the intact animal, suggesting that 
' insulin deficiency may augment its release.
It is well known that 2-deoxyglucose and mannoheptulose
sugars which are incompletely metabolised and which block the
intracellular metabolism of glucose, inhibit the release of
insulin both "in vitro" and "in vivo"^^^'^^^. It has been
proposed, therefore, that the metabolism of glucose within the
97 98
islet in some way serves as the signal for insulin release . 
The question is then raised as to v/hat is the mechanism of the 
stimulation of glucagon release by a low glucose concentration. 
The reciprocal release of glucagon and insulin demonstrated in 
Figure 8, suggested the possibility of a negative feedback from 
the same effector mechanism: glucose utilisation* The studies
using 2-deox.yglucose and mannoheptulose in these experiments were 
designed/
/designed to see if blocking glycolysis within the islet would 
stimulate glucagon release. The results, however, showed that 
the inhibitors had no effect on glucagon release. Thus, it 
appears that energy production from glycolysis is necessary for 
optimum release of insulin whereas it is not essential for 
glucagon release.
G E A p T 5 II 3 
SECTION 2
EFFECT OF STARVATION ON GLEGAGON RELEASE
rSmillARY
The effect of starvation on circulating iinmunoreactive 
glucagon (IRG) levels was reinvestigated, employing ne-w te cliniques 
which prevent degradation of glucagon in the assay. In addition 
isolated islets of Langerhans of the rat were used, to study the 
effect of starvation on the direct release of IRG and immuno- 
reactive insulin (iRl) from the pancreas, in order to overcome 
the confusing contribution to circulating IRG from intestinal 
sources. During a 3 day starvation period, peripheral venous 
IRG levels fell in 6 normal male subjects, but in 11 mongrel dogs 
starved for a similar period IRG levels remained unchanged.
Serum immunoreactive (IRI) levels declined during the starvation 
in the humans and dogs. Acute refeeding following starvation 
demonstrated carbohydrate intolerance, and in the human subjects 
this was associated with a delayed and excessive IRI response.
The serum IRG responses to a carbohydrate meal before starvation 
were variable and statistically insignificant in the human. After 
starvation, carbohydrate ingestion elicited a slow steady rise in 
circulating IRG levels. The demonstrated fall in circulating 
levels does not necessarily reflect the actual secretory status 
of pancreatic glucagon, since serum glucagon levels are probably 
derived from more than one source, including the pancreas and 
intestine. However, isolated islets o.f Langerhans from 3 day 
starved/
138
/starved rats released less IRI and IRG in various glucose 
concentrations, than control rats fed "ad libitum". It does 
appear, therefore, that the release of pancreatic IRG is decreased 
by starvation. It is suggested that glucagon may play a role in 
the regulation of insulin secretion during starvation and after 
carbohydrate ingestion.
2
Glucagon has been shown to have poværful glycogenolytic ,
3 99gluconeogenic , and lypolytic actions. During starvation,
virhen all of these processes are accelerated, increased glucagon
secretion might be expected. Although the behaviour of serum
100 101insulin during starvation has been well documented ’ , much
less is known about the changes in serum glucagon. Indeed, there
58,95
appear to be only two studies in which circulating glucagon
levels have been measured in man during starvation; each 
demonstrated a rise. The scarcity of reports on serum glucagon 
has been due largely to difficulties encountered in the assay of 
this hormone, due principally to degradation of glucagon by serum 
(chapter 1, section l). Since the previous studies reporting 
a rise in serum glucagon were conducted before recognising the 
extent of glucagon degradation during the assay, the effect of 
starvation on circulating glucagon levels was re-examined, 
utilising an immunoassay for glucagon with Trasylol added to the 
sera after blood centrifugation (Chapter 1, section 1).
It has recently become evident that immunoreactive glucagon 
(iRC) from the intestine, as well as the pancreas, contributes to
p p
the measured circulating IRG levels (Chapter 2, section 1).
Thus, changes in plasma IRG levels "in vivo" do not necessarily 
reflect changes in pancreatic IRG release, because of the 
unavoidable simultaneous measurement of gut glucagon. In 
addition/
140
/addition, therefore, to "in vivo" studies performed on humans 
and dogs, the release of IRG and immunoreactive insulin (iRl) 
from isolated islets of Langerhans of sta.i?ved and fed rats, was 
studied in order to directly study the release of pancreatic 
glucagon under these conditions.
laTERIALS AND METHODS
Six healthy lean male volunteers between 25 and 33 years of 
age, who had normal glucose tolerance, were studied. After over­
night fasting, blood was withdram daily before breakfast for 3 
or 4 days prior to the starvation period (control), for 
determination of seiTum IRG, IRI, serum acetoacetate, and plasma 
glucose. On the morning of the first day of starvation, 5 
of the 6 subjects were given a meal containing a calculated 100 gm 
of carbohydrate and blood was withdrawn serially for 3 hours 
thereafter for determined ion of the IRG, IRI, and glucose 
responses to a carbohydrate load in the control state. The 
subjects were then starved for the remainder of the day and for 
the next 2 days and allowed nothing by mouth except water, 2 cups 
of black unsweetened coffee per diem, sugarless gum, and sodium 
chloride ad libitum. The starvation was terminated on the 
morning of the fourth day by a similar breakfast in the same 5 
subjects and blood was withdrawn as mentioned.
Also, two young obese, but otherwise healthy males were 
starved/
141
/starved in the same fashion for 14 days and blood samples drawn 
daily for IRG, IRI, glucose and acetoacetate determinations, 
for several days prior to the starvation, during starvation, and 
during the refeeding period. One hundred gm. carbohydrate meals 
were given prior to starvation, and a similar meal to terminate 
the starvation. Bloods were withdrawn during these tests as in 
the lean subjects.
Eleven mongrel dogs were studied in a similar fashion and 
were allowed only water during the 3 day starvation period. In­
dwelling portal vein catheters were inserted at laparotomy, beyond 
the entry of the pancreatioo-duodenal vein. Studies were done 
only when the dog was again eating normally, and in no case sooner 
than 5 days postoperative. Portal blood was withdrawn on the day 
prior to the fast and daily during the starvation period for 
determination of IRG, IRI, and glucose. On the first day of 
starvation, the dogs were given an oral glucose tolerance test 
(GTT) by stomach tube (2 gm. glucose per kg. body weight), and a 
similar test was performed to break the fast on the morning of the 
fourth day.
Male wistar rats (400-500 gm.) were allowed to eat "ad 
libitum" (controls) or were denied all oral intake except water 
for 72 hours (starved) prior to study. Islets were isolated as 
described elsewhere in this thesis (Chapter 1, section 2) for 
measurement/
M 2
/measurement of IRI and IRG release. For blood collection a 
laparotomy was performed under ether anaesthesia and blood for 
measurement of circulating hormone levels and plasma glucose was 
obtained by exsanguination from the vena cava. For tissue 
extraction, control and 3 day starved rats were decapitated and 
the pancreas was removed and extracted for IRI and IRG content 
as described in this thesis (Chapter 2, section. 1 ),
RESGhTS
Starvation in humans and dogs
The mean serum IRG, IRI, acetoacetate, and plasma glucose 
concentrations in the human subjects are shown in Figure 10.
The acetoacetate concentration rose markedly and was still on 
the upward trend on the third day of the fast. The glucose 
concentrations declined progressively during the starvation. The 
mean IRI concentrations fell significantly on the first day 
(p ,01) and reached the lowest level on the third starvation 
day.
The IRG concentrations, which averaged 830 ppg. per ml, 
before starvation, fell slightly (p zi ,05) to 710 ppg, per ml, on 
the first day of the starvation, and continued to fall on the 
second and third days of starvation to 610 ppg, per ml, (p/L ,01) 
and 640 ppg, per ml, (p Z. *01) respectively. (Significance tested 
b;, the paired t - test). Rith refeeding there were rises in IRI 
glucose, and IRG to above control levels, but the decreases in the 
serum/
14^3
FIGURE 10
STARVATION IN H U M AN S  (n  = 6 )  ± S.E.M.
Control =Starve Refeed
■
Effect of starvation on plasma glucose, serum IRG, IRI, and 
acetoacetate in 6 lean human subjects. The fall in IRG was 
significant on each of the 3 starvation days (pzL 0 *0 5,/- 0.01, 
Z. 0.01, respectively) .
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/serum acetoacetate,
During 14 days fast periods for obese subjects glucose,
IRI, and IRG levels fell but there was a tendency for IRG levels 
to rise during the last fev/ days of the fast (Figure 11 ).
The changes measured during starvation in the dogs (Figure 
12) were less than those observed in the humans. The plasma 
glucose remained unchanged although the serum IRI fell during the 
starvation. Serum levels of IRG showed no significant chang'e 
during the 3 day starvation period.
Refeeding studies in humans and dogs
In 5 lean male subjects, the effects of a 3 day fast upon 
metabolic responses to an oral carbohydrate load are shov/n in 
Figure 13. All subjects developed carbohydrate intolerance 
and hypernormal IRI responses. The IRI response in the first 
30 minutes, however, appeared inadequate, as it was no greater 
than in the control state, despite much higher glucose levels.
Four of the 5 subjects in the control test showed a slight rise 
in serum IRG and one subject showed an enomous rise* The 
apogœs were transient and variable in timing, although they 
tended to occur in the first hour. The increase over the fasting 
level did not achieve significance at any time. In contrast to 
the control test, after the 100 gm, carbohydrate meal, 
administered at the termination of the 3 day starvation, the 
serum/
14E
FIGÏÏHE 11
I  §ê <  40-
Control StofVft Refeed120-t
Effect of prolonged starvation on plasma gluoose, serum IRG-, IRI, 
and acetoacetate in 2 obese human males* Serum IRI and IRG 
both fell, although there was a tendency for the IRQ to rise 
towards the end of the prolonged starvation*
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FIGURE 12
.4-^
Control Starve
70 -
6 0 -
1 5
% ^  3 0 -  
20 -
Days
Effect of starvation on portal vein plasma glucosej serum 
IRG and IRI in 11 dogs. There was no significant change 
in the glucose or IRO level but IRI levels progressively fell
FIGURE 13
î  M + S.E.M. 
o — o Control
#------# After 3 days starvation
200“
F 30  6 0  9 0  120 ISO
Minutes a fte r 1 0 0 6  oral carbohydrate
The response of plasma glucose, serum IHG, and IRI levels to oral 
100 gm# carbohydrate meals in 5 human subjects before and after 
3 days fasting. Glucose intolerance and an increased insulin 
response developed following starvation. The IRG rise over the 
fasting level achieved significance at no time during the control 
test, but in the poststarvation test the IRG rose steadily and 
was significantly higher than the fasting value at 30, 60, 90,
120 and 180 minutes after the OHO (p/, 0.02, Z. 0.05, ^  0.02, 
Z^O.01 ,/10.05, respectively). At only the 120 minute value did 
the starvation test reach higher levels than the control test
( p ^  0.02).
/serum IRG on all subjects rose steadily to reach a peak at 3 
hours. The rise over the fasting level was significant by the 
paired t-test at each time (p /_,02, /- .0 5, /h .02, .01, Z- . 0 5
at 30, 60, 90, 120 and 180 minutes respectively) and became 
significantly higher than the corresponding control test at 120 
minutes (p Z l ,02). The early glucagon rise in the control tests 
matched the early glucose and insulin rise whereas the late 
glucagon rise in the poststarvation test was concurrent with the 
delayed insulin and glucose rise.
In the 2 obese subjects the carbohydrate meal produced 
greater IRG rises poststarvation than prestarvation (Table 4)•
Theydid, however, show different behaviours in glucose tolerance 
and insulin responses. Subject S, who had normal gluoose 
tolerance prior to starvation, showed very slight deterioration 
following starvation, with a delayed insulin response similar to 
the pattern of the lean subjects. Subject B, on the other hand, 
had abnormal glucose tolerance with a delayed insulin response 
prior to starvation, and both abnormalities disappeared after the 
14 day starvation period.
Starvation in the dogs also produced intolerance, but without 
a change in IRI levels (Figure I4)' A rise in IRG to oral glucose 
in the control test (p Z,,02) remained unchanged by the 
starvation/
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\
— o Control
After 3 days 
starvation
S.E.M.
0
F 30  6 0  9 0  120
Minutes after oral glucose
150 180
The response of portal vein plasma gluoose, se:rum lEG, and IRI 
levels to oral gluoose (2 gm. per kg. "body weight) in 11 dogs 
before and after 3 days of starvation. Following starvation, 
the dogs developed glucose intolerance without a change in insulin 
secretion. The IRG response to glucose was significant in both 
the control and starvation tests (p/1 0.02 in both instances) but 
the starvation test did not become significantly higher than that 
of the control.
J. b
/starvation (Figure I4)»
Isolated islet and rat studies
The release of IRI ("iiIT/iO islets/30 min. mean + SE'vï) from 
control rat islets was higher (p .001) during incubation in 
300 mg./ glucose (1096 + 225) than in 30 mg./ (3OO + 42) as 
illustrated in Figure 15- Glucose concentrations of 30 and 
150 mg./ were not significantly different in effect on insulin 
release (p ZL .2) from control rat islets. Starved rat islets 
responded qualitively the same as controls, but significantly 
less insulin was released during incubations with 30 mg./
(186 + 33) (pZ-.Ol) and 300 mg/;b (403 + 56) (p/L .05).
Figure 15 also shows that increasing the glucose concentration 
of the incubation buffer results in less release of IRG 
{m]xgo/lO islets/3 0 min.mean f SFM) from control islets incubated 
with 300 mg./ (I088 4- .32) than it does from islets incubated with 
30 mg./ glucose (2.67 f .40)» This difference, however, did not 
achieve statistical significance (p 4L .2). Glucagon release from 
starved rat islets was diminished, achieving a significance from 
controls with both 30 mg./ (I.58 4- ,27) (p /L «05) and 300 mg./ 
glucose concentrations (I0O7 -H .17) (p ZL *05) °
Extending the incubation period to one hour resulted in 
continued impaired IRI release from the islets of the fasted animals, 
with 150 mg./ glucose in the medium (Figure 16) IRG release from 
starved/
5I
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FIGtTRB 15
EFFECT OF FASTING ON GLUCAGON 
AND IN SU LIN  RELEASE
28 41
1400" ! Fed
S.E.M.
200-
1000-
800-
.<0 600-
^  400-  
^  200-
4 0 27 39
30 150 300
G lucose  mg %
The effect of starvation on IRG and IRI release from isolated 
islets. The net hormone released during the 30 minute incubation 
period is expressed as the mean + SEM. The number of incubation 
vessels for each bar is shown at’the base of the bar.
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FIGUHE 16
GLUCAGON AND INSULIN RELEASE 
FROM FED AND FASTED RAT ISLETS
4-t
(12)
0— 0 Fed 
* — *  Fast
S.E.M.
30 
Minutes
( 13)
800-
^ -9 400
J
The effect of the incubation time on the release of IHG and IRI* 
The points represent the net hormone above the basal level at the 
beginning of the incubation* The number of incubation vessels 
for each point is shown in parenthesis.
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/starved rat islets was also less than controls, but the differ­
ence at 60 minutes was not statistically significant (pz_.1,).
The extractable IRI and IRG- content of fed and starved rat 
pancreases is illustrated in Table 5* Starvation had no 
significant effect on the concentration of either hormone in the 
pancreas.
The serum IRI and plasma concentrations in the vena cava 
were significantly less in fasted rats than in controls, but 
serum IRG levels were the same (Table 6).
mSGÏÏSSIQN
On first consideration it seems surprising that glucagon,
which is a, povrerful gluconeogenic hormone, should fall or remain
unchanged during starvation. It has been suggested that glucagon
may augment substrate availability during starvation through
58glycogenolysis and gluooneogenesis . The results of our studies
indicate that glucagon may not contribute significantly to glucose
mobilisation during fasting. Cahill and co-workers^^^, however,
presented evidence that starvation results in decreased glucose
mobilisation, whereas lipid mobilisation and utilisation are
increased. Glucagon is a prompt, potent, hepatic glycogenolytic 
2 79
agent <, thus explaining its possible role in acute hypoglycaemic
states. Since fasting rapidly depletes rat liver glycogen 
102stores and muscle glycogen serves as the main source of 
carbohydrate/
15
TABLE 5
EFFECT OP STARVATION ON EXTRACTABLE GLUCAGON ANN
INSULIN CONTENT OP RAT PANCREAS
Insulin
m units/gm. 
wet weight
Glucagon
m \ig/m 
wet weight
Control 15.6 + 3.7 (6 ) 27.5 + 7.0  ( 6)
Starved 
3 days
1 5 . 3  + 2 .1  ( 5 ) 2 0 . 5  + 4 . 5  ( 5 )
Means -F S*E*M.
N in parenthesis
TABLE 6
SERDIÆ IRG, IRI, AND PLASMA GLUCOSE
BEFORE AND AFTER 3-DAY STARVATION
Control 3-day Starvation
Serum 2? + 3.8 (13) 8 4- .s"' (13)
IRI
Serum ,801 -i- .087 (20) .876 + *099 (22)
IRG
mpg/ml
Plasma 153 + 7.1 (8) 85 + 4 '^ (10)
Gluoose
mg 4/
All values represent mean + S.E.M,
Numbers in parentheses refer to number of observations. 
*p< .001 compared with control.
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/carbohydrate (pyruvate) during starvation"*then the demand for 
glucagon as a carbohydrate mobiliser in the starved animal is 
probably not as great as in the fed.
Although glucagon is lipolytic in pharmacological amounts'^
its ultimate physiological effect on lipolysis in the intact animal 
99.105is debatable . Other hormones with potent lipolytic
properties, i.e. epinephrine and growth hormone, are secreted in 
greater quantities during starvation^^^*^^^ and may stimulate the 
increased lipolysis which occurs during starvation. Elevation 
of free fatty acid levels has recently been shown to depress 
circulating glucagon l e v e l s ^ E l e v a t e d  free fatty acids 
probably contribute to the impairment of glucagon release during 
fasting*
The studies of Cahill and colleagues"*implicated an 
insulinrglucose feedback mechanism in the regulation of substrate 
utilisation during fasting. It maybe that other hormones, such 
as glucagon, also help to regulate insulin secretion. Samols and 
associates'^ and Grookford and co-workers^^ have shown that 
glucagon is a powerful stimulator of insulin secretion "in vivo". 
Possibly glucagon plays a greater role in the regulation of insulin 
secretion than in the réutilisation of energy substrates during 
starvation. This would help to explain the observed parallel fall 
in blood glucagon and insulin levels during starvation.
Interpre tation/
158
/interpretation of changes in circulating peripheral or
portal vein blood IRG levels must be made with caution because of
a contribution to these levels from more than one source.
Specifically, an intestinal mucosa extract has been found to contain
biological  ^ immunological properties  ^  ^ similar to
glucagon. Circulating IRG levels do not fall to zero after
pancreatectomy in dogs (see chapter 2, section 1) indicating another
(presumably intestinal) source of circulating IRG. Also the
4-1studies of Ketterer and c0- workers suggest that changes in the 
secretion of glucagon could have biological effects, such as 
stimulation of insulin release, without causing a detectable change 
in immuneassayable peripheral IRG levels. In the absence of a 
method of differentiating the relative contributions from the 
pancreas and the intestine to circulating serum IRG levels, it must 
be concluded that circulating IRG is a measure of IRG from both sources. 
It is possible, therefore, that actual changes in pancreatic IRG 
secretion during starvation might differ from the changes that 
are reflected in the peripheral and portal veins of starved man 
and dog, respectively. However the finding that the release of 
glucagon wa,8 impaired by starvation, does suggest that some of the 
changes in circulating IRG in the human studies might be due to 
diminished pancreatic release of glucagon.
The diminished insulin release of starved rat islets in this 
study/
159
/study was most pronounced during incubation in a high glucose
concentration. Since the pancreatic insulin content was not
altered, starvation appears to have impaired the insulin secretory
process more than the synthetic and storage mechanisms. The ■
mechanism of the suboptimal insulin release from the fasted rat
109islets cannot be explained. Malaisse et al , who made similar 
observations with a pancreas slice technique, theorised that 
diminished activity of islet cell glycolytic enzymes ma,ybe 
responsible for this blunted insulin release following fasting.
This diminished insulin release "in vitro" is consistent with the 
fall in vena cava IRI levels.
The results of this study,showing a fall in circulating
glucagon levels during starvation, maybe opposite those of Unger
58 95and associates and of Lawrence because of differences in
technique. At the time of their study, Trasylol was not incorpor­
ated in the glucagon assay system and, therefore, degradation of 
labelled hormone in the assay and changing blood proteolytic
activity during the starvation may have contributed to their results.
110Recently, however, Samols has reported no change in circulating 
IRG levels in fasted human subjects.
This study has confirmed the previous reports of the glucose 
intolerance and insulin resistance with hypersecretion of insulin 
that are observed after oral glucose administration to subjects 
starved/
/ 101111/starved for short periods ' . Species variability may explain
the failure of the starved dog to develop hyperinsulinism after
oral gluoose, since the acetoacetate response of dogs to fasting
112is also known to be different from the human However, the
3 day starvation in the dog may have resulted in an absolute
insulin deficiency, a phenomenon thought to occur in humans after
101longer periods of starvation .
The significance of the post starvation IRG rise after oral
carbohydrate is not knovm. A similar response in non fasted 
95, 56
humans has been observed previously by others. An attractive
hypothesis would be to consider that the IRG rise is from an
23 23intestinal origin” , that it stimulates insulin release , and that 
it stimulates larger amounts of insulin during a meal following 
starvation, in order to overcome the insulin resistance and glucose 
intolerance of starvation.
C H A P T E R  3 
SECTION 3
THE EFFECT OP ENTERIC FACTORS ON CLUCACON 
AND INSULIN RELEASE
oSUlVnviARY
The effect of the enteric factors secretin, and pancreozymin 
(PPZ) were studied on the secretion of imniunoreactive insulin (iRl) 
and immunoreactive glucagon (IRG), utilising anaethetised mongrel 
dogs with multiple venous catheters "in situ", and isolated 
pancreatic islets from the rat. Secretin by continuous infusion 
(0 .25 u/min.) produced no change in the levels of IRI and IRG in 
the pancreatic venous blood of dogs despite causing a copious 
flow of pancreatic juice. PPZ, however, caused a dramatic increase 
in both hormone levels. Concomitant with these effects there was 
a rise in the plasma gluoose and a fall in free fatty acids (FPA). 
Following PPZ, the concentration of IRG in a jejunal vein was 
much less than for the pancreatic vein, and in dogs after 
pancreatectomy, PPZ was without effect on IRG secretion, suggesting 
that the IRG in the gut was not influenced by PPZ. PPZ, secretin, 
and gastrin, failed to cause a release in IRI and IRG release from 
isolated pancreatic islets. It is suggested that enteric factors 
may mediate their effects on IRI and IRG release by indirect means, 
or that the isolated islets are insensitive to factors which 
rapidly release IRI and IRG*
3For many years the enteric hormones have been recognised to
be of considerable importance in the regulation of exocrine
pancreatic secretions. The possibility that these enteric
hormones may also play a role in controlling the endocrine pancreas
was suggested by the demonstration that an oral glucose load is
115disposed of more rapidly than an intravenous load and that the 
oral route of administration is associated with a greater rise in
116circulating insulin levels . These observations prompted
subsequent studies to define the effect of various gut factors
117 55 118on islet cell hormone release. Secretin  ^ * and
119pancreozymin have each been reported to stimulate insulin
55secretion. Unger et al have also shown that pancreozymin
stimulates glucagon release. Gastrin has slight and transient
55effects on insulin secretion . Another enteric factor has been
identified which has biological properties and immunological
properties similar to glucagon (Chapter 2, section 1), It has,
however, recently been suggested that the immunoreactive material
from the gut does not in fact have the biological properties of
pancreatic glucagon and that the function of this "gut glucagon"
23maybe to stimulate insulin secretion after eating
The interpretation of changes in peripheral IRG levels is 
difficult because of the contribution to these levels from at 
least two sources, the intestine and the pancreas. Therefore, 
it was the purpose of this study to examine the effect of 
pancreo zymin/
164
/panoreozymin and secretin on immunoreactive insulin (iRl) and 
IRG secretion and to identify changes in circulating IRG levels 
with an origin in the pancreas, intestine, or both. In addition 
it was considered that the study of enteric factors on IRI and IRG 
release from isolated pancreatic islets (Chapter 1, section 2) 
may give some insight into the possible role of these factors in 
controlling the endocrine pancreas and their mechanism of action.
MATERIALS AND METHODS
Using mongrel dogs (20 - 30 kg.) under barbiturate 
anaesthesia, catheters were passed through an abdominal incision 
into the craniopancreatico-duodenal vein, a large jejunal vein, 
and into a peripheral vein; care was taken not to obstruct the 
pancreatic vein. For the pancreatic vein it was found desirable 
to insert a 21 guage paediatric thin-wall needle in the direction 
of blood flow. At the time of blood sampling, the pancreatic vein 
at its entry into the portal vein was occluded with a simple thread 
snare to prevent reflux from the portal vein. The main pancreatic 
duct was catheterised and the accessory duct ligated.
The islets were prepared from 200 - 300 gm. male albino Wistar 
rats (fed ad libitum) by the technique described in Chapter 1, 
section 2 of this thesis. Ten per cent pure oholecystokinin- 
pancreozymin (PPZ) (N0 .26741) and purified secretin (N0 .I6741) 
were obtained through the kindness of Professor D.E.Jorpes, G.I.H, 
Research/
16
/Research Unit, Chemistry Department, Karolinska Institutet,
Stockholm. Gastrin prepared by a modification of the method
120
of Gregory and Tracy was kindly supplied by Dr. T. Aoki of 
the Department of Surgery, University of Washington, Seattle*
Two pg. of this gastrin preparation were necessary to produce 
maximum effects on biological assay. The amounts of IRI and 
IRG present in these substances are shown in Table 7«
RESULTS
Dog Experiments
The effects of PPZ and secretin on the levels of IRI and 
IRG in pancreatic blood, and of plasma glucose and free fatty 
acids (EFA) in peripheral blood are shown in Table 8 and 
graphically in Figure 17* After a 10 minute control period, 
secretin was constantly infused into a peripheral vein at a rate 
of 0.25 U/min. which was sufficient to produce a copious flow of 
pancreatic juice in all dogs. Following 30 minutes of secretin 
infusion, 75-100 Ivy units of PPZ were rapidly infused into a 
peripheral vein. During secretin infusion alone there were no 
significant changes in the levels of IRG, glucose, IRI and FFA. 
Following PPZ, the IRI rose from a pre-injection level of 
1089 t 777 pU/ml. (mean + 8.D.) to a level at 2 minutes of 
3390 f 1819 pU/ml. (p ^  .02) and these values were maintained for 
15 minutes. IRG levels also rose from I.04 + *49 mpg./ml. to a 
peak/
TABLE 7
IRI IRG
(p units) (m )
Pancreozymin
(per Ivy unit) 4 .24
Secretin
(per unit) 0 0
Gastrin
(per pg.) 0 0
The amounts of immunoreactive insulin (IRI) and 
immunoreactive glucagon (IRG) in the test substances*
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FIGURE 17
Secretin I.V. 0.25 units/min.
^  too un its  pancreozym in (,V.
Glucose
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The effect of secretin and PPZ on IRI and IRG levels in the 
pancreatic venous effluent and on plasma glucose and FFA in 
the peripheral vein. The experiments were performed on 6 
dogs under anaesthesia at laparotomy. There was no change 
following secretin infusion alone, but following PPZ there 
were dramatic increases in IRI (p Z-*02), IRG (p .02) and 
plasma glucose (p .01). FFA levels fell but this fall 
did not achieve significance*
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/peak at 2 minutes of 2.35 *<■ *94 mpg,/ml, (pxl.02). Plasma 
gluoose rose at 10 minutes (from 112 to 137 mg,/lOO ml.) (pzL *01 ) 
suggesting a glycogenolytic effect of the endogenously released 
glucagon, but PPA levels fell (l.18 + ,39 m2q./h to .89 -t* *14 at 
30 minutes), although this did not achieve statistical significance.
The relative values for IRI and IRG in the pancreatic, 
jejunal, and peripheral veins are shown in Figures 18 and 19 
respectively. The changes in pancreatic vein insulin were 
similarly reflected in both the peripheral and jejunal veins, 
although peak values in the peripheral and jejunal veins occurred 
in the 5 10 minute sample rather than the 2 minute. Values for
the pancreatic vein blood were 30 - 70 times greater than those for 
peripheral blood. (Canine insulin standard was used in these studies 
which resulted in a correct dilutional effect). IRG changes in 
the peripheral and jejunal veins were of small degree (Figure 19) * 
The peak value in the jejunal vein occurred at 10 minutes, but 
only very small increments in the peripheral vein values were found 
from 5 to So minutes. Jejunal vein levels were slightly greater 
than peripheral vein levelsî jejunal vein: peripheral vein
ratios at 2, 5? 10, 15 and 20 minutes after PPZ were found to be:
2.2, 1.6, 1*4? 1*2 and 1*2 respectively. Hov/ever, there were much
higher ratios of pancreatic vein: peripheral vein levels at 2, 5?
10, 15 and 20 minutes after PPZ; these were 6*3, 3*6, 2*4, 2*2 
and/
FIGURE 18
IRI SECRETION IN 6 DOGS
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Comparative values for IRI in the pancreatic, jejunal and 
peripheral veins in 6 dogs during seoretin-PPZ infusion.
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RG SECRETION IN 6 DOGS
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Secretin l.V. 0.25 units/ml
^  100 units pancreozymin l.V.
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80
Comparative values for IRG in the pancreatic, jejunal and 
peripheral veins in 6 dogs during secretin-PPZ infusion.
i g
/and 2«4 respectively. These results indicate that PP2 had a 
greater effect on pancreatic I.RG secretion than on the release of 
IB.G"like material from other sources, such as the intestine.
To find whether PPZ had any effect on gut IRG secretion, the 
pancreas was totally excised in 5 dogs, and the secretin and PPZ 
stimuli repeated. When IRG levels reached a steady state, 
usually 60 minutes hut not greater than 90 minutes after 
pancreatectomy, secretin and PPZ were once again infused* This 
time there was no change in IRI, IRG or plasma glucose levels 
(Figure 20) indicating that PPZ probably influences the release of 
pancreatic IRG only.
Islet Studies
PPZ (Figure 21), gastrin (Figure 22), and secretin (Figure 23) 
were all ineffective in promoting either IRI or IRG release at 
varying concentrations of stimuli and glucose (not all of the 
concentrations of test substances used are shown in the figures).
PPZ at concentrations greater than 5 units/ml* recorded signifi­
cant amounts of IRG in the t^ vessels, so as to make interore-u
tation of the results difficult.
PISGUSSIOR
This study has confirmed previous reports of the effect of
b‘5 119PPZ on IRI secretion in the dog ' but the results conflict with
121 122unsuccessful attempts to promote IRI release with PPZ in man *
The/
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FIGUEE 20
IRI AND IRG 
SECRETION IN 3 PANCREATECTOMIZED DOGS
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In 5 dogs following panoreatectomy, seoretin-PPZ infusion had 
no effect on peripheral vein glucose and IRI values, and jejunal 
and peripheral vein IRG values*
FIGURE 21
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PPZ had no effect on IRI and IRG release from isolated 
pancreatic islets. Uumhers of groups of 10 islets are 
shown at foot of column. Ihe empty columns are control 
islets.
FIGURE 22
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Gastrin had no effect on IRI and IRG release from isolated 
pancreatic islets. Rumbers of groups of 10 islets are 
shown at the foot of the column. The empty columns are 
control islets.
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Secretin had no effect on IRI and IRG release. N-umbers of 
groups of 10 islets are shown at the foot of the columns. 
The empty columns are control islets.
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/The absence of an effect of PPZ on IRI secretion "in vitro" is
123in agreement with the results of Turner and McIntyre and 
124Turner who observed no increase in IRI release from rabbit
pancrea.s preparations using Jorpes' PPZ, The conflict may be
explained by species variation - that the effect of PPZ may only
be seen in the dog, but could also be due to the different
preparations of PPZ employed. The vrarkers reporting that PPZ
has active insulin stimulating properties have all used purified
119,55preparations obtained from Professor I), B, Jorpes  ^ ,
/ 125Recently, however, Dupre et al have found that PPZ can enhance,
in man, the rise in blood IRI concentration that occurs after
intravenous infusion of glucose and arginine.
Our inability to stimulate IRI release with a secretin
infusion is in contrast to the numerous reports of the promotion
117 55 118of IRI secretion by this hormone '  ^ . The small dose and
mode of infusion which were employed, although insufficient to
promote IRI secretion, were large enough to maintain a flow of
123 124-pancreatic juice. Turner and McIntyre and Turner also could
observe no IRI release from rabbit pancreas "in vitro" incubated
with Jorpes* secretin, although Boot's pure secretin had insulin
stimulating properties. These results then are in agreement with
the negative results of secretin on IRI release from isolated
126islets, produced in the present study, Pfeiffer et al 
demonstrated/
17
/demonstrated stimulation of insulin secretion from pancreas
slices using Vit rum secretin, V/hen crude preparations of a
stimulus are employed, the possibility exists that impurities
may have produced the observed effects. It has been reported
that optimal effects of secretin on IRI secretion may only be
127seen in the presence of hyperglycaemia ,
It has 8,1 so not been possible to demonstrate any effect of
gastrin "in vitro", on either IRI or IRG release. The effects
55of IRI release by gastrin reported by Unger et al were only small
and transient and may not be specific.
The study has demonstrated that PPZ injection causes a
prompt release of IRG, which produced higher levels of IRG in the
pancreatic vein than in a gut vein, confirming the observations 
55of Unger et al , It was further established that PPZ does not
stimulate the release of IRG in pancreatectomised dogs. This
might lead to the conclusion that IRG from pancreas and gut are
23different molecules as Unger et al suggest. This is not 
necessarily so, however, as the different responses to stimuli 
maybe explained by different receptor sites in the intestine and 
the pancreas. The rise of blood glucose after PPZ is consistent
with a glycogenolytic dose-related action of glucagon, and v/as also
55 119seen in the experiments of Unger et al , Meade et al found no
change in the blood glucose concentration after PPZ, but they used
smaller/
/smaller doses than Unger^^, The rise in IRG was not associated
99with a rise in FRA as one might expect from Lefebre's data 
which showed that small doses of intraportal glucagon were 
associated with a rather delayed rise in FFA levels. The 
failure of FFA to rise in our experiments might be explained by 
the antilipolytio effects of the IRI secreted simultaneously, 
or the minute amounts of IRG which appeared in the peripheral 
circulation might have been insufficient to cause lipolysis.
It might be argued that the effect of PFZ was due to the 
presence of contaminating IRI and IRG in the preparation. The 
amounts of contaminating IRI and IRG were small, being approxi­
mately 24 mpg. IRG and 4OG pU. IRI per 100 Ivy units PPZ infusion. 
An effect of the contaminating IRI can be discounted, as a rise in 
peripheral circulating IRI levels following PPZ infusion v/as not 
seen in the dogs whose pancreas had been removed. (Figure 20). 
Similarly the PPZ infusion did not cause a rise in circulating 
IRG levels in dogs following pancreatectomy (Figure 20) so that
increased IRG levels in the intact dogs following PPZ must have
been secondary to a direct effect on the A cells. It is possible,
however, that the contaminating 24 mpg. IRG may have caused the
41IRI secretion in the intact dogs, as Ketterer et al have reported
IRI secretion following the infusion of 100 mpg.IRG into a portal
vein. However, any secretion they recorded was slight, transient 
and/
180
/and variable, and it seems unlikely, therefore, that 24 mpg. IRG
would have caused the large, consistent and rather prolonged effect
on IRI secretion observed in the present studies. The contrast
between the "in vivo" findings of PPZ being a potent stimulator
of IRI and IRG release and the negative effects "in vitro", may
suggest that PPZ influences the endocrine pancreas by indirect
128means, perhaps by changing blood flow to the pancreas . The
isolated islets may respond poorly to factors which rapidly
release IRI and IRG. The isolated islets have been found to
respond reproducably and predictably to changirgglucose
concentrations in both IRI and IRG secretion (Chapter 3?section 1).
A stimulus such as starvation (Chapter 3, section 2) has also
produced marked effects on hormone secretion from the isolated
islet. It is concluded that the isolated islet may be more
responsive to chronically administered stimuli than to substances
which produce their effects rapidly.
Apart from its well known function on the exocrine pancreas,
it is interesting to speculate what part pancreozymin may play
in the control of the endocrine pancreas after ingestion of food.
Many factors are now known to cause IRI release after eating.
Figure 24 summarises the events which may occur. Amino acids
129
cause IRI release, yet without marked hypogiycaemla . Fajans 
130
et al argue that this may be the result of rapid gluconeogenesis 
from/
PIGÜHE 24
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Hyperglycemia
Blood glucose
Hypoglycemia
Glucagon Insulin
Proteins
Glucose 
Amino acids 
Fats 
Secretin 
Gut glucagon 
Pancreozymin
A schematic representation of metabolic events which might 
occur after eating. Numerous factors stimulate insulin 
release. Pancreozymin stimulates glucagon release perhaps 
to prevent hypoglycaemia after eating protein.
/from the protein or that proteins cause the release of both IRT
and IRG, These authors refer to one experiment in which the oral
administration of arginine stimulated a rise in circulating IRG 
130levels . In addition IRG stimulation may be mediated via
pancreozymin as the ingestion of protein is probably the greatest
131stimulus for pancreozymin secretion . Thus pancreozymin might
be secreted after a large protein meal,not only to stimulate the
exocrine pancreas, but also to cause the secretion of IRI and IRG,
the IRG acting to prevent hypoglycaemia.
Several factors of intestinal origin, not only secretin and
55 132pancreozymin but also gastrin , glucagon , and other unknown 
124
substances have been implicated as mediators in the enhanced
insulin response that is seen after orad. glucose as compared to
intravenous glucose. It is as yet premature to assign any
physiological function to these intestinal factors on the
endocrine pancreas until more accurate methods for their assay
become available. Attempts to produce physiological secretion
127of secretin and pancreozymin by intestinal acidification have 
failed to stimulate insulin release.
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C H A P T E R  3 
SEGTIOM 4
THE EFFECT OF GLUCAGOII ON INSULIN RELEASE
1 8  4
SUMMARY
The effect of glucagon on inununoreactive insulin (iRl) 
release was studied in intact dogs, and isolated pancreatic 
islets from rats. In the islet studies glucagon was confirmed 
to he effective in stimulating IRI release hut only at the high 
concentration of 10 pg./ml. and only at a concentration of 
glucose of 150 mg. per cent, hut not at 30 or 300 mg. per cent. 
However crude acid alcohol extracts of gut containing immuno- 
reactive glucagon were ineffective in promoting IRI release.
In the dogs very small doses of glucagon administered intra- 
portally during hyperglycaemia were effective in promoting IRI 
secretion.
Perhaps the most exciting and even surprising new property
for glucagon has been that of its ability to stimulate insulin
secretion, independent of any hyperglycaemia, produced^^^^^.
Pharmacological doses of glucagon have been used in these
4-1experiments, but recently Ketterer et al have shown that
physiological amounts of glucagon, infused into the portal vein
of dogs will cause an insulin rise. Indeed the reports of the
insulin stimulating properties of glucagon have tended to conflict
with the classical role of glucagon in providing glucose.
The finding of an immunological substance in the gut which
resembles glucagon (Chapter 2, section 2) has raised speculation
23
as to its role# Unger et al suggest that it may stimulate 
insulin secretion and this would be consistent with the finding 
of a rise in gut glucagon following oral glucose (Chapter 3, 
section 1).
Consequently the effect of both pancreatic and gut IRG on 
insulin secretion has been assessed both "in vivo", and also on 
the isolated pancreatic islet model (Chapter 1, section 2).
mTHODS M D  MTBRIALS 
Crude gut immunoreactive glucagon (IRG) was prepared from 
acid-alcohol extracts of rat gut (jejunum, ileum and colon. 
(Chapter 2, section 1). There were 8 mpg. of IRG equivalents 
and 20 p units of immunoreactive insulin (IRI) per mg. of 
lypholised/
186
/lypholised weight of the extract.
Isolated pancreatic islets from male V/istar rats 
(200 - 300 gm.) were prepared as described elsewhere in this 
thesis (chapter 1, section 2).
Mongrel dogs at laparotomy were prepared with multiple 
catheters "in situ" as described in Chapter 3? section 1,
Crystalline beef-pork glucagon (Eli-Lilly) was used as the 
pancreatic glucagon preparation throughout the studies. This 
glucagon has 2 units of IRI per |ig.
RESULTS
Islet Studies
Crystalline beef-pork glucagon at a concentration of 
10 jag./ml, increased IRI release at 15O mgv/ glucose (p »05)
but not at 30 or 300 mgf/ glucose (Figure 25)* Lesser 
concentrations of glucagon, and increasing the concentration to 
100 pg./ml,, were ineffective in promoting IRI release. At a 
concentration of 100 pg./ml. of glucagon, there was so much 
contaminating IRI as to render interpretation of the results 
difficult. In these experiments in the control vessels without 
glucagon, a glucose effect ok IRI release was noted, there being a 
greater IRI release at 300 mgv/ glucose than 30 mg.^ (p Z- .01) 
(Figure 25)»
Crude gut IRG (Figure 26) was however ineffective in 
promoting IRI release at varying concentrations of glucose and IRG. 
At/
FIGURE 25
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The effect of crystalline beef-pork glucagon (10 pg,/ml.) on 
IRI release. Glucagon produced a significant effect (p ^  .05) 
at 150 mg. per cent, glucose only. The difference between 
the IRI release in the control 30 mg. per cent, glucose flasks 
and the 300 mg. per cent, glucose flasks is significant at the 
p ZL .01 level. Number of groups of 10 islet incubations is 
shown at foot of columns.
FIGURE 26
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0 25 125 250
Gut extract ( IRG m/ig /  ml)
An. acid alcohol extract of rat gut containing IRG was ineffective 
in promoting IRI release. Numbers of groups of 10 islets are 
shown at foot of the columns.
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/At the high concentrations of the crude gut preparation there 
was much contaminating IRI material as to possibly influence the 
results.
Dog Studies
Two dogs in which tolbutamide had been infused followed by 
glucose (Chapter 3? section 1), were given glucagon intraportally 
60 minutes after the glucose when hyperglycaemia was still present, 
(figure 27). Glucagon in a dose of 0.05 ]%g. was sufficient to 
produce rises in circulating IRI levels in both dogs, although 
further and larger glucagon infusions (O.25 - O.^fgO? failed to 
produce further IRI secretion. Neither dog showed distinct 
rises in peripheral circulating IRG levels after O.O5 )ig, glucagon 
intraportally, although 1 dog showed clear changes after 0 .25 and
*5 Rg.
It is concluded that the dogs under the conditions of the 
above experiments can respond by rises of circulating IRI and 
glucose to intraportal infusions of glucagon in amounts which 
cannot be detected in the peripheral blood by immunoassay. The 
physiological doses of intraportal glucagon in a dog may then be 
less than 0.25 » and possibly in the range O.O5 - 0.1 jig. or
even less.
DISCUSSION
The "in vivo" experiments have confirmed the insulin 
stimulating/
FIGURE 27
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In 2 intact dogs, 60 minutes after the infusion of 25 gm. 
glucose intravenously, the effect of small, rapid, intraportal 
infusions of crystalline glucagon on peripheral vein IRI and 
IRO levels is shown*
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/stimulating properties of gluoagon^^^^^, and the data agrees with
41that of Ketterer et al v^ ho showed that intraportal doses of
glucagon which could barely be detected in the peripheral blood
by immunoassay were never the less associated with insulin
secretion. The insulin secretion promoted by glucagon in the
present experiments was produced at a high glucose concentration
77 132 133and several workers ’ ’ have reported enhancement of
glucagon-stimulated insulin secretion when there is hyperglycaemia-
The "in vitro" experiments show less convincing evidence of
an effect of glucagon on insulin release. At a concentration of
10,000 times physiological, an effect of slight significance was
74produced. Coore and Randle were unable to produce an effect
133 1 34 1 35"in vitro", but since then all reports ' ' consistently
show an effect, although in the "in vitro" work there is less
agreement as to the influence of glucose concentration on
1 32glucagon-stimulated insulin release. Malaisse et al were
unable to promote insulin secretion with glucagon "in vitro" until
the glucose concentration was raised to 150 mg.^ and they noted
further enhancement at 300 mg.^. Lambert et al^  observed
glucagon-induced insulin release from isolated foetal pancreatic
tissue even in the absence of glucose, but the effect was enhanced
1 35by the addition of glucose to the media. fevrim and Recant ,
on./
/on the other hand, noted a greater release of insulin hy glucagon 
from rat pancreas slices in the absence of glucose than in its 
presence.
If glucagon has physiological importance in the control of 
insulin release, then one might expect a positive correlation in 
the release of these hormones from the pancreatic islet. However, 
glucose concentrations appear to have an opposite effect on their 
release, hypoglycaemia stimulating glucagon release and hyper- 
glycaemia stimulating insulin release. Adrenalectomy (Chapter 3, 
section 5) stimulated glucagon release from the islets but 
inhibited insulin release. ïheoploy 1 line, and tolbutamide both 
stimulate insulin release from the islets, but have no effect on 
glucagon release, and diazoxide and epinephrine inhibit insulin 
release but have no effect on glucagon release (iC. H, Buchanan 
and J. So Vance,preliminary results). Starvation, however, 
(chapter 3? section 2) does inhibit both insulin and glucagon 
release from the islet, and this is the only condition which the 
author has met where the 2 hormones have been secreted concomit­
antly. In addition most reports have indicated that glucagon- 
stimulated insulin release is enhanced by hyperglycaemia. Yet 
during hyperglycaemia pancreatic glucagon secretion is inhibited 
(chapter 3, section 1). It seems unlikely, therefore, that 
glucagon/
195
/gluoagon will promote insulin secretion when the blood glucose 
concentrations are high, although the effect maybe mediated at 
lower glucose concentrations.
Perhaps, as Unger et al ' suggest, it is gut glucagon which 
acts to promote insulin secretion. In the author's study crude 
gut IRQ- did not promote insulin release but this lack of effect 
may simply be related to the small dose employed (0.25 )ig« IRC 
equivalents),
An alternative explanation of this conflicting data which 
maybe offered, is that because of the proximity of the A and B 
cells within the islet, the A cells maybe able to affect the 
B cells without necessarily reflecting changes in the glucagon 
concentration outside of the islet.
19^
C H A p T E R 3 
SECTION 5
THE EPEECT OF PITUITARY - ADRENAL HORMONES 
ON GLUCAGON RELEASE
13 \ m m m
Adrenalectomy in rats increases immunoreactive glucagon 
(iRGr) release from isolated islets but decreases IRI release. 
Cortisone therapy prevented these events occurring. The IRG 
content of the pancreas of the adrenalectomised animals was 
reduced suggesting that adrenalectomy affected the release of 
glucagon rather than its synthesis and storag'e. Rats treated 
with AOTH also showed increased IRG release from the islets.
ACTH may therefore be the mediator of the increased IRG release 
from isolated islets of the adrenalectomised rat. It is 
suggested that these various hormones which have potent effects 
on carbohydrate metabolism may exert control mechanisms over one 
another.
The adrenal corticosteroids have potent effects on
carbohydrate metabolism. They promote gluconeogenesis and
137 138hepatic glycogenosis . In addition it has long been
known that the administration of corticosteroid drugs may produce 
decreased glucose tolerance which is reversible on discontinuing' 
t h e r a p y ^ R e c e n t l y  it has been shown^^^*^^^*^^^ that the 
insulin response to glucose is increased by pre^treatment with 
corticosteroids in normal, diabetic and pre-diabetic subjects. 
Several workers too have reported that adrenooorticotrophin 
(AGTH) stimulates insulin release in animals^^^?^^^*^^^^^^^.
Glucagon also promotes gluconeogenesis^ and also increases 
insulin secretion^^*^^. It was considered, therefore, of interest 
to study the effect of pituitary «-ad renal hormones which have a 
known effect on carbohydrate metabolism on the release of 
glucagon from the pancreatic islets.
hlETHODS ARP MATERIALS 
Pancreatic islets were isolated as described elsewhere in this 
thesis (chapter 1, section 2) from male wistar rats (200 - 300 gm.) 
The rats were adrenalectomised surgically under barbiturate 
anaesthesia and thereafter were maintained on normal saline 
drinking water and fed "ad libitum". Control rats were "sham 
operated", the rats being exposed to the whole surgical procedure, 
except that the adrenals were not excised. The mortality rate 
amongst/
197
/amongst the adrenaleotomised animals was only slightly greater 
than the sham operated, hut the adrenalectomised rats lost slightly 
more weight than the sham operated. Some of the adrenalectomised 
animals were maintained on intraperitoneal injections of cortisone 
acetate (1 mg. cortisone per 100 gm. animal).
Studies were performed 4 or 5 days post operatively.
■RBSÏÏLT5
The results are shown in Table 9 and Figure 28, Islets 
from adrenalectomised animals released less immunoreactive insulin 
(IHI), hut increased immunoreactive glucagon (IRO) (p .01 in 
'both instances) when incubated in 150 mg. per cent glucose. VJhen 
cortisone was administered to the adrenalectomised animals the 
increased release of IRG was almost abolished, and the decreased 
release of IRI wa.s over corrected.
The pancreases from 7 sham operated and 7 adrenalectomised 
animals were extracted for IRI and IRG content (Figure 29)••The 
adrenalectomised animals showed a significant reduction (p / ..05) 
in the IRG content of the pancreas, but did not differ from 
controls in IRI content,
RISaUSSIOR
The effect of adrenalectomy on IRI release from the islet
149confirms the report by Malaisse et al , who also showed increased 
lEl/
18
TABLE 9
IRI (Mean + sm) IRG (Mean + Sm)
3agZl.Q .isle.'ts/ jO. mln. wg./lO islëts/30 min.
Sham operated 245 ± 28 639 h* 106
Adrenalectomised 157 ± 27* 1238 -i- 197*
Adrenalectomised
-h Cortisone 972 + 116* 965 t 272
(^Achieved significance (p ,01 ) in comparison with sham 
operated)•
The release of immunoreactive insulin (iRl) and immunoreactive 
glucagon (iRC) from isolated islets of sham operated and 
adrenalectomised rats.
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of the pancreas (p .05) although IRI content was not affected 
The numbers at the foot of the column refer to the numbers of
pancreases extracted.
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/iRI release from cortisol treated rats. The observation, however, 
that adrenalectomy augments IRG release from the islet is a novel 
one. The explanation for this phenomenon could be multiple. 
Cortisol therapy apparently abolished the increased IRG release but 
this does not necessarily mean that cortisol lack produced the IRG 
release. One possibility is that adrenalectomy stimulated ACTH 
production. ACTH stimulates insulin release and it is possible 
that it may stimulate glucagon release. In some preliminary work, 
ACTH injected animals showed a 274^ increase in IRG release, and 
when ACTH was added **in vitro** to the islets (1 U/ml.) IRG release 
was also increased by 180^ although IRI release was unaffected.
(K. R* Buchanan, J. E. Vance, A. E. Kitabchi. Preliminary observ­
ations). This might suggest, therefore, that it was ACTH, rather 
than corticosteroid lack, which stimulated IRG release.
Another explanation which remains is that it is the removal of 
the adrenal medulla rather than cortex which is the critical factor.
The catecholamines exert important actions in carbohydrate
150 2
metabolism, mainly on gluconeogenesis and glycogenolysis ' .
However when aminoglutethimide (Elipten), a drug which inhibits
151the synthesis of corticosteroids , was injected into rats IRG 
release was increased 101^ although IRI release was unaffected. 
Epinephrine (2 pg./ml.) addition **in vitro” to the islets 
inhibited IRI release (55/^ ) but had no effect on IRG release.
K. R. Buchanan/
202
/K. D. Buchanan, J, E, Tance, A. E. Kitabchi. Preliminary 
observations).
The reduction in the glucagon content of the pancreases 
from the adrenalectomised animals suggests that although IRG 
release was increased, synthesis probably was not. The results 
suggest that the mechanism of the increased IRG release following 
adrenalectomy may be caused by the resulting stimulation of 
AGTH, although the results are by no means conclusive in this 
respect. It does suggest, however, that these various hormones 
which have potent effects on carbohydrate metabolism may exert 
control mechanisms over one another.
gC H A P T E R  4
CLIHICAL STUDIES OP A FMILY SHOWIHG EXCESSIVE SECRETION 
OP ALL PANCREATIC ISLET CELL HORMONES
Symptomatic and asymptomatic members of a family with 
multiple endocrine adenomatosis (pancreatic islet cell tumours, 
parathyroid hyperplasia., and hyperadrenocorticism) were studied 
in detail. The only living member of the first generation, and 
all five direct descendants studied, had excessive secretion of 
insulin. Three of these six showed increased levels of plasma 
glucagon. Of the five members of the second and third 
generations tested, four had increased fasting plasma gastrin 
levels. Ho definite clinical features could be related to the 
hypergluoagonaemia and the patients are compared with reports in 
the literature of patients with glue ago noma. A hypothesis l.s 
formulated suggesting that the primary defect in the multiple 
endocrine adenomatosis syndrome may lie in an abnormal 
proliferation of islet cells which is genetically determined, 
and the changes in other glands may be secondary to over 
production of islet cell hormones.
4-7McGavran et al in. 1966^' described a patient considered 
to be suffering from an alpha-cell carcinoma of the pancreas.
The patient had mild diabetes mellitus. Hepatomegaly was present 
and at laparotomy a tumour of the pancreas was found which on 
histology proved to be an alpha cell carcinoma. The neoplasm 
was shown to have large amounts of glucagon by immunoassay and 
hypergluoagonaemia was present in the patient. Yoshinaga et al 
(1966)^^^ also described a patient with a pancreatic A-oell 
tumour* The subject had high levels of glucagon-like activity 
in the serum although immunoassay was not performed.
Both of the above patients presented with diabetes mellitus 
and both had clinically apparent abdominal tumours. To the 
author’s knowledge these are the only two cases of glucagonoma 
reported, and possibly only the case of McGavran et al can be 
fully accepted because of the use in this case of the more 
specific immunoassay method.
The following is a report of a family with multiple endocrine 
adenomatosis (llilA) in which studies have revealed that all the 
hormones of the pancreas - glucagon, insulin and gastrin - have 
been affected by the process.
METHODS
All subjects consumed a diet providing 300 gm. of carbo­
hydrate daily for 3 days prior to testing. The following tests 
were/
/were performed in random order on consecutive days in the resting 
state after an overnight fasts 100 gm* oral glucose tolerance 
test, 1 gm. intravenous tolbutamide test, and 1 mg. intravenous 
glucagon test.
Subject 5 received 300 mg. of diazoxide every 6 hours during 
most of her tests but some tests were repeated while off the drug. 
Subject 3 was studied one year following total gastrectomy, and 
Subject 6 was studied following subtotal parathyroidectomy but 
prior to pancreatectomy.
Plasma immunoreactive gastrin (iRGa) levels were kindly 
measured by Dr. James McGuigan, Washington University School of
Medicine, St. Louis, Missouri, using a double antibody technique
153 154-developed in his laboratory ^  *
CLINICAL SUMMARIES
Figure 1 outlines the pedigree of this family. The 
propositus (No. 5) was seen at age 6 because of hypoglycaeraic 
seizures. As summarised in Table 1, she had 3 separate pancreatic 
operations for diffuse islet cell hyperplasia with two micro­
adenomata (1950)> diffuse islet cell hyperplasia with islet cell 
adenomata (l955)j and metastatic islet cell carcinoma (1964)*
She also manifested precocious puberty, and underwent a unilateral 
adrenalectomy for diffuse hyperplania and a subsequent subtotal 
removal/
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Pedigree of a family with multiple endocrine adenomatosis.
TABLE 1
Age
(y e a r)
6
(1950)
7
(1951)
S ym p to m s , signs 
& c lin ic a l course
H yp o g lycem ic  
s e iz u re s , s lig h t 
o b e s ity , pubic  
h a ir
H y p o g lycem ia  
re s o lv e d , s te ro id  
t re a tm e n t stopped; 
S ligh t c l i te r o -  
m e g a lly
H o rm o n e
a s s a y s
S u rg e ry
2 /3  pau- 
c re a te c  • 
to m y
Su r g ic a l  
p a th o lo g y
D i f f u s e  
i s l e t  c e l l  
h y p e r p l a ­
s ia  & m i c -  
r  cade  n o m a - 
t a
P o s t o p e r a t i v e  
cou rs c
Hy]]og] y c c m ia  
t r e a t e d  w i t h  
A C T H  8i c o r t i ­
sone f o r  9 m o  =
9
(1953)
F u r th e r  g ro w th  of 
pubic h a i r ,  onset 
of m e n s e s , b re a s t  
d eve lo p m en t; 36 
h o u r fa s t caused  
h y p o g lyc em ia______
24 hour  
u r in e  17 - 
K S , 17-O H  
g n o rm a l
11
(1955)
H y p o g lycem ic
se izu re s
24 ho u r  
u r in e  
17-K S  
21. 5 m g
E x c is io n  of 
2 p a n crea tic  
adenom as & 
m a jo r ity  of 
head of 
pane. R ight 
a d re n a le c ­
to m y_______
D iffu s e  is le t  
c e ll h y p er - 
p la s ia . 2 
is le t  adeno­
m a ta ; a d r e ­
na l c o r t ic a l 
h y p e rp la s ia
H y p e rg ly c e m ia  
re q u ir in g  
in s u lin  th e ra p y  
fo r  3 m onths.
14
(1958)
O n set of h irs u tis m
18
(1962)
H e a v y  b e a rd , shaved  
d a ily ; co rtiso n e  
and estrogen  
th e ra p y  s ta rte d
24 hour
u r in e
17 - K S
23, 4 m g ,
p la s m a
c o rt is o l
15 p f i / 1 00 m l
20
(1964)
C o rtis o n e  and 
es tro g e n  th e ra p y  
stopped; h y p o ­
g ly c e m ic
s e izu re s
H y jjc r -  
in s u lin is m  
(See te x t. 
T a b le  I I )
S ubtotal 
p a n c re a te c ­
to m y; e x c i­
sion of 
m e ta s ta t ic  
h e p atic  
nodules; 
re m o v a l of 
2 /3  le f t  
a d re n a l
Is le t  c e ll 
adenom ata  
in pancreas  
and l iv e r ;  
a d re n a l 
c o rt ic a l  
adenom a & 
hy]3er- 
p la s ia______
P e rs is te n t
hyp o g lycem ia ;
d iazo x id e
th e ra p y
s ta rte d
24
(1968)
R e la t iv e ly  
a s ym p to m atic  on 
d iazo x id e  th erap y : 
p e rs is te n t o b e s ity , 
h ir s u t is m , 
c lite ro m e g a lly _____
See te x t,  
Figs. # #
Case history of Propositus (No. 5)*
/removal of the remaining adrenal because of an adenoma and
hyperplasia. Presently, she is maintained relatively free from
hypoglycaemic symptoms with diazoxide therapy. A detailed account
155of her initial response to diazoxide has been published
Patient 6 had intermittent hypercalcaemia for two years and at
age 21 subtotal parathyroidectomy revealed hyperplastic changes
in all 4 glands. At that time asymptomatic glucose intolerance
and fasting hypoglycaemia prompted further studies (vide infra).
A total pancreatectomy was performed revealing diffuse islet cell
hyperplasia and adenomata. He is presently asymptomatic, receiving
insulin and pancreatic enzyme replacement. Patient 3 had a total
gastrectomy for the Zollinger Ellison syndrome prior to this study.
Pancreatic tumour tissue at that time revealed a gastrin-like
156material by bioassay, reported in detail elsewhere . He is 
now asymptomatic but has residual pancreatic and duodenal 
adenomata. Subject 1 was studied at the Mayo clinic in 1924 for 
peptic ulcer symptoms. He had gastric hyperacidity and a single 
duodenal ulcer at surgery. An operation two years later, follow­
ing intractable abdominal pains and severe diarrhoea, revealed 
"ulcers at the other end of the stomach". He died soon thereafter 
and no autopsy was performed. Presumably he also had the 
Zollinger Ellison syndrome. The other members of the family 
studied/
/studied (Nos. 2, 3, 5, and 8) have had no symptoms of endocrine 
dysfunction and have not undergone any operative procedures 
involving the endocrine glands.
HESULTS
The test results obtained in the study of this family are
summarised in Table 2. Values were considered to be increased
or decreased if greater or less than two standard deviations
from mean control values, respectively. The mean fasting
values in our assays of control subjects are for inimuno re active
insulin(lHl) 18 + pU/ml. (Mean f 8.D.), and for immunoreactive
glucagon(lRGl) 380 + 180 pyig./ml., and IRGa 425 ppg./ml. The
area under the IRI response curves following each of the test
157stimuli was calculated for each subject . Of 12 control 
subjects only one showed a significant rise in IRGl after oral 
glucose, and in 6 control subjects after intravenous tolbutamide 
no change in circulating IRGl levels were noted.
As shown in Table 2, two members of the family (Nos. 5? 6) 
had elevated fasting IRI levels and all subjects in the genetic 
line of transmission (Nos. 2, 3, 4? 5? 6, 7) had exaggerated IRI 
responses to oral glucose and tolbutamide. Four of the subjects 
(Nos. 3, 4j 5, 6) had elevated fasting IRGa levels* One subject 
(6) had elevated fasting IRGl values (mean of 12 fasting values 
771 ppg./ml.). Three subjects (Nos. 3, 4? 6) had elevated IRGl 
responses/
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12
/responses to oral glucose and two (Nos. 3 and 6) had excessive 
responses to intravenous tolbutamide. Prior to pancreatectomy 
subject 6 had elevated fasting levels of IRI, IRGl and IRGa.
The pancreatic adenomata found at operation in this subject 
contained extraotable IRI and IRGl (IRGa not yet measured), and 
the elevated fasting hormone levels all returned to normal 
following pancreatectomy. Three members of the family have ha,d 
intermittent hypercalcaemia (3, 5? 6). Basal hourly gastric 
acid secretion was increased in subject 3 and showed borderline 
increased levels in subject 6.
The propositus (No, 5) was studied in January, 1968, while 
receiving diazoxide therapy and again after stopping the drug 
(Figures 2 and 3). Oral glucose tolerance, intravenous 
tolbutamide, and intravenous glucagon tests were performed on 
consecutive days after overnight fasting while continuing to 
receive 300 mg. of diazoxide every 6 hours by mouth. The tests 
were then repeated in the same order after discontinuing 
diazoxide therapy; the first repeat test was performed 24 hours 
after stopping the drug. During the 3 day period while off 
diazoxide, she consumed a 300 gm. carbohydrate diet divided into 
8 feedings per 24 hours, with the last feeding given at 3 a.m., 
or 5 hours before starting the tests, each day.
As/
FIGURE 2
9;
...
3.0
IRG 
m/iq/ml | q-
O' 
150
IR I  '00 
/^U/ml gQ.
O R A L  G T T
on diazoxide 
o ff diazoxide
3 0 0 i
Blood 200 
Glucose 
mg% 100
I I
6 0  120
Minutes
180
Plasma 20- 
FFA 
/i.Eq/m! 10
0 “ 1---------------1—
6 0  120
Minutes
180
Oral glucose tolerance tests performed on propositus 
(subject 5) while on and off diazoxide. Shaded lines 
represent the normal mean values#
o  ■
FIGïïRill 3
IRG 
m/ig/ml j q-
0
600n
IR I 400- 
//U /m l 200-
I.V. TOLBUTAMIDE
3.0-
2.0-
0-
300-1
Blood 200- 
Glucose 
mg% 100-
0-
60 
Minutes
120 ^0
I.V. GLUCAGON
on diazoxide 
off diazoxide
150-|
100-
50-
0
300-1
200-
100-
0
60 120 180
Minutes
Intravenous tolbutamide and glucagon tests performed on 
propositus (subject 5) while on and off diazoxide. Shaded 
lines represent the normal mean values.
1/As can be seen in Figures 2 and 3, fasting normoglycaemia 
associated with, on two out of three occasions, slight elevations 
of fasting IRI levels was noted while on diazoxide therapy. When 
diazoxide therapy was discontinued,fasting asymptomatic hypo- 
glyoaemia with elevated IRI levels developed. Fasting plasma 
IRGl levels while receiving diazoxide were approximately 50^ 
lower than the levels while off medication.. Elevated plasma 
IRGl levels in response to hypoglycaemia were not observed. The 
oral glucose tolerance tests (Figure 2) while on and off diazoxide 
therapy, elicited qualitatively similar responses: no change in
plasma IRGl levels, glucose intolerance associated with delayed 
but excessive IRI release, and only a slight delayed fall in FFA 
levels.
Three members of the family have had intermittent hyper- 
calcaemia ( R o s .  3> 5> 6). The following tests were normal in all
subjects: haematoorit, white blood count and differential;
serum sodium, potassium, chloride and carbon dioxide; fasting 
serum immunoreactive growth hormone, serum thyroxine; 24 hour 
urinary 5"tiydroxyindolaoetic acid, lY-ketosteroids and 
17“hydroxysteroidsI skull x-rays of the sella turcica.
DI3CÏÏSSIQR
It cannot be accurately deduced from these case histories 
what may be the clinical features of a glucagon excess state.
These/
/These patients had abnormalities of several endocrine glands
and therefore the clear cut effects of glucagon excess will be
confused with the effects produced by excess of other hormones.
Two of the subjects (3 and 6) had elevated levels of plasma IRGl
following tolbutamide which might be expected to produce
secretion of pancreatic IRGl (Chapter 3, section l) whereas
three (3, 4 and 6) had elevated plasma levels of IRGl after
oral glucose which promotes secretion of IRGl from the gut
(Chapter 3> section 1). Neither of the two subjects who had
elevated levels of pancreatic IRGl showed any particular features
which might be related to this. Subject 3 had normal oral glucose
tolerance, but subject 6 had a mild diabetic oral glucose
tolerance* Hov/ever, subject 6 also had hyperinsuiinlsm, and
oral glucose intolerance is a well known feature of insulinoma 
1 58
subjects . In addition both subjects with the hyper- 
glucagonaemia of pancreatic origin had hyperinsuiinlsm and 
hypoglycaemia, so that it might be argued that the hyper- 
glucagonaemia in these subjects might be due to the stimulus of 
chronic hypoglycaemia. However, patient 5 with severe protracted 
hypoglycaemia did not have evidence of hypergluoagonaemia.
The only conclusion that may be dravm. from the glucagon 
measurements in this particular family, is that glucagon may be 
another/
/another hormone which is involved in the multiple endocrine
adenomatosis syndrome. It is not possible, however, to conclude
what effects the glucagon may have been producing. Reports in 
47 152the literature suggest that glucagon excess states may be
associated with diabetes mellitus of a maturity onset type. 
Although there is in the literature only one accurately 
documented case of glucagonoma, there are reports of alpha cell 
carcinomas of the pancreas not associated with the Zollinger 
Ellison syndrome which have varying aberrations in oarbo-
159hydrate metabolism, from steroid induced renal glycosuria to 
overt diabete847'152,160,161^
There is, as yet, no evidence to incriminate glucagon 
excess as a cause of idiopathic diabetes mellitus. Glucagon 
hypersecretion in the circulation has only been detected in 
patients with pancreatic tumours as the patients in this report. 
Because of the inability to accurately assess pancreatic glucagon 
secretion in human subjects, the question as to whether glucagon 
plays a role in the pathogenesis of diabetes mellitus remains 
to be answered.
The most widely accepted theory of the pathogenesis of the 
multiple endocrine adenomatosis syndrome is that a common genetic 
defect in each affected endocrine gland leads directly to cellular 
proliferation/
1/proliferation, independent of humoral f a c t o r s " * T h e  
predominant involvement of the pancreatic hormones in this study, 
however, leads to interesting speculation as to another possible 
explanation for the syndrome. The hypothesis is suggested that 
the genetic defect involves primai'ily the pancreatic islets and 
that involvement of other endocrine glands results from chronic 
overprbduction of islet cell hormones.
Support for this concept is gained from recent provocative
161clinical associations. Poloyan et al reported two patients 
with alpha cell hyperplasia, hypergl%oagonaemia and hyperpara­
thyroidism. They have shown that glucagon injections in rabbits 
caused acute hypocalcaemia, and, over a prolonged period, para­
thyroid hyperplasia"* Alvioli et al"*^  ^found that after
glucagon administration in dogs, a substance v;ith the biological 
properties of calcitonin was released. The ability of calcitonin 
to stimulate parathyroid hyperplasia is further supported by the 
observation that calcitonin can be extracted from medullary thyroid
167
carcinoma , a tumour which is associated with parathyroid 
hyperplasia"*^^. It may, therefore, be that alpha cell hyper­
plasia and chronic hypergluoagonaemia stimulate calcitonin release, 
thereby producing hypocalcaemia. During prolonged compensatory 
secretion of parathormone to maintain eucalcaemia, the parathyroids 
become hyperplastic and eventually develop autonomous function, 
and clinical/
19
/and clinical hyperparathyroidism. In an analagous fashion,
insulin acts directly or indirectly to stimulate the release of
169grov/th hormone, ACTH and glucocorticoids, and epinephrine 
Chronic hyperinsulinism might accelerate each of these processes, 
and over the course of years lead to hyperplasia and subsequently 
to functioning tumours of the pituitary, adrenal cortex and 
adrenal medulla.
SiaMARY AND COÏÏCLUSIOHS
The construction of a reliable immunoassay method for 
glucagon ha<s formed the basis of this thesis. The major factor 
in the building of a good assay was the recognition of the 
susceptibility of glucagon to attack by proteolytic enzymes, 
a fact which at first escaped the notice of earlier investigators, 
Trasylol, a proteolytic enzyme inhibitor, has proved to be an 
efficient means to prevent this enzyme degradation. The assay 
was able to detect as little as 20 ppg* of glucagon.
The application of the assay to measurement of immuno- 
reactive glucagon (IRO) in tissues and body fluids, revealed 
that IRG was not only present in the pancreas but was also 
detected in much of the alimentary tract, mainly the small and 
large intestines. It was apparent too that circulating IRG was 
derived from both enteric and pancreatic sources. Clearance 
studies of glucagon showed that glucagon disappeared rapidly from 
the body and that the liver was a major site for the degradation 
of glucagon. Ro difference in the clearances of enteric and 
pancreatic glucagons was noted. However immunological differ­
ences appeared to be present between the enteric and pancreatic 
glucagons, enteric glucagon reacting less strongly with glucagon 
antibody than pancreatic glucagon.
When assessing the factors which might affect the release of 
glucagon, consideration had to be given to the factors cited above 
which/
/which would complicate the studies. It was realised that an 
assessment of factors affecting the release of glucagon from both 
the pancreas and gut would have to be undertaken separately.
A direct assessment of factors affecting the pancreatic release 
of glucagon was made possible by application of a method for 
isolating the islets of Langerhans of rat pancreas. The use 
too was made of dogs with venous catheters situated in pancreatic 
and gut veins, so that a separate measurement of IRG changes from 
blood draining the pancreas and gut could be made. Studies of 
animals in whom the pancreas was removed was also made, in order 
that factors affecting gut glucagon release could be assessed in 
the absence of the pancreas*
It was realised also that studies of peripheral circulating 
IRG levels may fail to record changes in gut and pancreatic IRG 
secretion as much of the glucagon would be removed in its passage 
through the liver* Thus many of the measurements of IRG were 
done in pancreatic, jejunal, colonic or portal blood prior to its 
passage through the liver* Wherever possible experiments were 
duplicated both by "in vitro" pancreatic islet studies and "in 
vivo" dog or human studies, in order that observations could be 
confirmed by these two different approaches.
Because of certain already established pharmacological actions 
of glucagon on carbohydrate metabolism, the effect of changing 
glucose/
9 9 ^^  w  O
/glucose concentrations was first of all studied. IRG secretion 
from the pancreas was found to increase during acute hypoglycaemia 
whereas no effect was noted on gut IRG secretion, Hyperglycaemia 
in contrast inhibited IRG secretion from the pancreas but once 
again had no effect on gut IRG secretion. Oral glucose did, 
however, stimulate gut IRG release but did not influence pancreatic 
IRG release,
A study of the effect of the enteric hormones on IRG release 
was made because of previous reports of the effect of these hor­
mones on insulin release. Pancreozymin was found to exert a 
potent effect on both IRG and insulin release from the pancreas, 
although it had no effect on IRG release from the gut. Secretin 
and gastrin did not however possess any IRG releasing properties 
from either gut or pancreas.
It was considered probable that glucagon might be an important 
hormone in the control of the metabolic changes during starvation 
particularly through its pharmacological actions on gluconeogenesis 
and lipolysis. However contrary to this hypothesis, circulating 
levels of IRG were found to fall during starvation in human subjects 
That this fall might be due to diminished pancreatic IRG secretion 
was suggested by the finding that the release of IRG from pancreatic 
islets of starved rats was also reduced.
Amongst the other factors tested on glucagon release, results 
were/
/were obtained to suggest that some of the pituitary adrenal 
hormones may influence IRG release from the pancreas. In 
particular adrenocorticotrophic hormone (ACTH) probably increased 
IRG release.
Studies were also made of the inter-relationship of glucagon 
and insulin secretion. Glucagon stimulated insulin release both 
"in vivo" and "in vitro". However simultaneous measurements of 
glucagon and insulin release from pancreatic islets seldom 
produced a direct correlation in the amounts of each hormone 
released as one might expect if endogenous glucagon were stimu­
lating insulin release.
It is still premature to confidently attach to glucagon a 
unified concept of its physiological role. It is probable that 
like insulin it has many actions and that many factors influence 
its release. The number of factors which influence insulin release 
has reached almost embarrassing proportions. These include many 
of the monosaccharides - fructose, ribose, mannose, galactose and 
glucose, although glucose still enjoys pride of place -, free 
fatty acids, octanoic acid, ketone bodies, proteins and amino acids 
ACTH and glucagon, pancreozymin, secretin and gastrin, theophylline 
and caffeine, Beta adrenergic blockers such as isuprel, and many 
others. It seems probable that these many factors which influence 
insulin secretion do so through a common mechanism such as the 
cyclic/
5
/cyclic 3 5 adenosine monophosphate mechanism as Malaisse et
i 32al (1967) suggest. This thesis reports several factors which 
influence pancreatic IRG release. These include hypoglycaemia, 
pancreozymin and ACTH* Reports in the literature in either 
preliminary or abstract form suggest that other factors influence
/I nn
pancreatic IRG release. Ohneda et al (1968) report that amino 
acids increase the release of IRG from the pancreas and Madison
•i 1V1
et al (1968) have shown that elevation of free fatty acids 
inhibit the release of pancreatic IRG. Just as with insulin the 
further widespread application of the immunoassay method for 
glucagon is likely to see the growth of a number of factors 
affecting glucagon secretion.
At the present state of our knowledge one can see pancreatic 
glucagon as being a hormone of importance in maintaining normo- 
glycaemia either during short episodes of fasting or during the 
reactive hypoglycaemia which occurs after eating. It is probable 
that it is just after food that the relationship which the enteric 
hormones pancreozymin and secretin have with insulin and glucagon 
plays its role. Following a meal secretin and pancreozymin will 
be released and this in turn will influence the secretion of 
insulin and glucagon, the insulin being released to mobilise 
substrate and the glucagon being more directed towards the pre­
vention of hypoglycaemia which would be prone to occur particularly 
after/
/after a high protein, low carbohydrate meal. The amino acids 
may mediate their effects on pancreatic IRG release only via 
pancreozymin which they are known to influence. H, S. Track 
(1968)^^^ describes fascinating and provocative structural 
similarities among gastrin, secretin, insulin, glucagon and 
possibly pancreozymin as well. This structural similarity might 
lead one to suspect that these hormones might have certain 
properties in common. Glucagon, pancreozymin, secretin and 
gastrin all affect insulin secretion. Secretin in addition to
4 Y c
gastrin has recently been reported by Lazarus et al (1968) ' to 
have hyperglycaemic, glycogenolytic properties. Gastrin has 
enjoyed eminence ever since its association with the Zollinger 
Ellison syndrome, but pancreozymin and secretin have to some 
extent remained metabolically dormant in a little backwater of 
exocrine pancreatic function. They now emerge with challenging 
new functions. It seems eminently possible that pancreozymin 
and secretin will fall victim to the immunoassayist*s axe.
Until this happens then the full metabolic role of these hormones 
and their association with insulin and glucagon vd.ll remain 
enigmatic.
It is difficult to assign an exact place to the property of 
glucagon in stimulating insulin release. It seems contradictory 
that a hormone which is secreted when there is glucose need, should 
influence/
/influence the secretion of insulin which is a hormone of 
glucose abundance. The thesis has demonstrated too that pan­
creatic glucagon release is inhibited by hyperglycaemia.. It may 
be, however, that glucagon may influence insulin release at 
relatively low glucose concentrations in order to maintain basal 
insulin secretion.
In summary then glucagon's physiological role may be in the 
prevention of hypoglycaemia which might occur during short periods 
of fasting, or the reactive type which occurs after a meal. Its 
effect on insulin secretion may only operate at near fasting or 
low blood sugar concentrations. It is considered too that 
glucagon is probably a hormone which is of more importance during 
acute metabolic events rather than chronic. This is suggested 
by the lack of influence of chronic starvation on glucagon 
secretion.
The whole problem of the nature and role of the IRG in the gut 
is even more uncharted than that of pancreatic IRG, Factors which 
affect the release of pancreatic IRG do not influence the release 
of the gut material, and the reverse is also true. Similarities 
concerning its clearance and degradation as compared with pan­
creatic IRG were found. Immunological dissimilarity between the
two IRG materials was however noted, and this work has been
\ 17Textended by Reding (1968) who in a recent communication showed 
that/
/that hy the use of a grossly discriminating antibody pancreatic 
IRG could be separated from gut IRG in the peripheral blood. The 
fact that the enteric material rises after oral glucose may suggest 
that its role lies in the possible promotion of insulin secretion. 
However the assignment of this material to a role remains purely 
conjectural. So, too, must its true nature and its relationship
p  3
with pancreatic glucagon. Unger et al (1968) did consider that 
the gut IRG possessed none of the biological properties of glucagon 
but this work was at variance with the earlier reports of Kenny and 
Say (1962)^^ and Malcman and Sutherland (1964)^^ who both reported a 
glucogenolytic-hyperglycaemio substance in gut. More recently, 
however, ITalverde et al (1968)^^^ describe two fractions of 
glucagon immunoreactivity in the gut, one being of similar 
molecular weight to pancreatic glucagon and sharing at least some 
of its biological properties, and the other being a larger 
molecular weight substance and not possessing the biological 
properties of pancreatic glucagon. However, neither of these gut 
fractions reacted with glucagon antibody in a manner identical v/ith 
pancreatic glucagon. The elucidation of the nature and role of 
enteric immunoreactive glucagon material remains an exciting 
challenge for the future*
Glucagon's role in disease is unlcnown. Apart from the one 
or two cases of gluoagonoma reported (Chapter 4); no clearly 
defined assocation of glucagon with any disease state has yet been 
described/
/described. It is highly provocative to consider that an 
abnormality of glucagon secretion may in fact lead to diabetes 
mellitus. This possibility is not so remote as the association 
which was once thought to occur between growth hormone secretion 
and diabetes mellitus. It remains, however, a possibility 
which still has to be tested. So too are the thoughts that 
glucagon deficiency may play a role in certain hypoglycaemic 
syndromes.
There remain certain technical difficulties which lie in the 
way of the elucidation of these problems. Application of the 
glucagon immunoassay to human subjects remains unsatisfactory 
but recent advances in methods of improving immunoassay 
sensitivity (Miles and Hales, 1968^^^) and in the differentiation 
of pancreatic and gut glucagon (Heding, 19^8 ) promise that
these difficulties will soon be overcome. The future of glucagon 
is only just being realised.
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